<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206974</article-id><article-id pub-id-type="doi">10.1101/2025.06.16.659792</article-id><article-id pub-id-type="archive">PPR1037570</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genome-wide CRISPR base-editing screening defines drug response networks in <italic>Leishmania</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Angel</surname><given-names>Jorge Arias del</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Link</surname><given-names>Fabian</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">3</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Nicole Herrmann</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ekici</surname><given-names>Ilkem</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wawra</surname><given-names>Konstantin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwind</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zorn</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haggarty</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="A3">4</xref></contrib><contrib contrib-type="author"><name><surname>Weidt</surname><given-names>Stefan K</given-names></name><xref ref-type="aff" rid="A3">4</xref></contrib><contrib contrib-type="author"><name><surname>Ritchie</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="A4">5</xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Michael P</given-names></name><xref ref-type="aff" rid="A4">5</xref></contrib><contrib contrib-type="author"><name><surname>van Zandbergen</surname><given-names>Ger</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beneke</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Cell and Developmental Biology, Biocentre, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fbnyb24</institution-id><institution>University of Würzburg</institution></institution-wrap>, <city>Würzburg</city>, <country country="DE">Germany</country></aff><aff id="A2"><label>2</label>Division of Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00yssnc44</institution-id><institution>Paul-Ehrlich-Institut</institution></institution-wrap>, <city>Langen</city>, <country country="DE">Germany</country></aff><aff id="A3"><label>4</label>Shared Research Facilities (SRF), MVLS, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vtgdb53</institution-id><institution>University of Glasgow</institution></institution-wrap>, <city>Glasgow</city>, <country country="GB">United Kingdom</country></aff><aff id="A4"><label>5</label>School of Infection and Immunity, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vtgdb53</institution-id><institution>University of Glasgow</institution></institution-wrap>, <city>Glasgow</city>, <country country="GB">United Kingdom</country></aff><author-notes><corresp id="CR1">
<label>#</label>To whom correspondence should be addressed. <email>tom.beneke@uni-wuerzburg.de</email>
</corresp><fn id="FN1" fn-type="current-aff"><label>3</label><p id="P1">Current Affiliation: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Translational Neuroinflammation and Automated Microscopy TNM, Göttingen, Germany</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>16</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">Understanding the genetics of drug response in the protozoan <italic>Leishmania</italic> is critical for treatment strategies but is hindered by the parasite’s lack of RNAi and non-homologous end-joining. Here, we addressed this using CRISPR/Cas9 cytosine base editing for genome-wide loss-of-function screening in <italic>L. mexicana</italic>. The resulting datasets, accessible at <ext-link ext-link-type="uri" xlink:href="http://www.leishbaseeditdb.net/">www.LeishBASEeditDB.net</ext-link>, revealed numerous novel resistance and sensitivity biomarkers across five compounds: Sb<sup>III</sup>, miltefosine, amphotericin B, pentamidine, and the experimental arylmethylaminosteroid 1c. Key findings include transporter-linked cross-resistance, opposing drug responses among paralogs, and collateral sensitivities between sterol and sphingolipid metabolism. Among 41 validated candidates, we identified sterol defects in two novel amphotericin B resistance markers, discovered a regulator of tubulovesicular localization of the miltefosine transporter complex, and uncovered evidence for flagellar-mediated drug uptake. Parallel genome-wide fitness and motility screens mapped essential genes and revealed persister-like phenotypes. Our approach enables powerful reverse genetic screens across <italic>Leishmania</italic> species, advancing drug mechanism studies and guiding combination therapy designs.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P3">Many parasitic diseases face the increasing challenge of emerging drug resistance, and <italic>Leishmania</italic> spp., protozoan parasites transmitted by the bite of infected sand flies, represent an excellent experimental model for studying antiparasitic resistance due to their clinical relevance and diverse resistance mechanisms (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R8">8</xref>). In <italic>Leishmania</italic>, resistance to key anti-leishmanial drugs, such as antimonials, pentamidine, miltefosine, and amphotericin B, frequently arises through alterations in drug influx and efflux systems, notably involving ATP-binding cassette (ABC) transporters (<xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R13">13</xref>), the aquaglyceroporin AQP1 (<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R22">22</xref>) and the miltefosine transporter complex (<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R27">27</xref>). Resistance is also associated with changes in membrane composition, particularly lipid and sterol profiles, especially in the case of amphotericin B and miltefosine (<xref ref-type="bibr" rid="R28">28</xref>–<xref ref-type="bibr" rid="R40">40</xref>).</p><p id="P4">Beyond membrane dynamics, resistance mechanisms in <italic>Leishmania</italic> can be transferred via extracellular vesicles (<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R42">42</xref>) and often involve gene copy number variations as well as point mutations in genes associated with transcription, translation, mitochondrial activity, metabolic networks, and cell signalling (<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R43">43</xref>–<xref ref-type="bibr" rid="R50">50</xref>). This means <italic>Leishmania</italic> parasites possess a diverse set of largely drug-specific resistance mechanisms, though some mutations, such as those in AQP1, the <italic>Leishmania</italic> miltefosine transporter (LMT), and various ABC transporters, have been linked to cross-resistances (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R54">54</xref>).</p><p id="P5">Conversely, fewer reports exist on mutations that increase drug sensitivity and it remains largely unclear whether mutations conferring resistance to one drug routinely alter susceptibility to others, highlighting a critical gap in our understanding of drug interaction profiles and collateral sensitivities (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R56">56</xref>). Understanding the genetic basis of both resistance and sensitivity is vital for guiding treatment options, including combination therapies, and therefore essential to make future treatment policy decisions (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R56">56</xref>).</p><p id="P6">To address this knowledge gap, we conducted a genome-wide functional analysis in <italic>L. mexicana</italic> using our recently developed cytosine base editing (CBE) platform, overcoming limitations inherent in <italic>Leishmania</italic> that preclude standard CRISPR and RNAi approaches (<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R58">58</xref>), the latter having been transformative for identifying drug resistance and sensitivity mechanisms in the related parasite <italic>T. brucei</italic> (<xref ref-type="bibr" rid="R59">59</xref>). Our screen enabled the identification of extensive drug response networks and dozens of novel resistance and sensitivity biomarkers in <italic>L. mexicana</italic>.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>A Genome-Wide Loss-of-Function Screen for Phenotyping in <italic>Leishmania</italic></title><p id="P7">A library consisting of 38,422 protein-targeting CBE sgRNA expression cassettes was generated (<xref ref-type="supplementary-material" rid="SD1">supplementary file 1</xref>), with 1 to 6 sgRNAs per gene (~5.2 on average). These sgRNAs were designed to introduce STOP codons within the first 50% of coding sequences in 94% of all protein-coding ORFs. Additionally, 1,000 non-targeting control sgRNAs were included. The entire library was integrated into the 18S rRNA SSU locus via Cas12a-mediated recombination, at a rate of 500 parasites per sgRNA. Expressing one sgRNA per cell (<xref ref-type="bibr" rid="R58">58</xref>), this enabled the functional assessment of 7,378 unique and 340 multi-copy or isoform genes (<xref ref-type="fig" rid="F1">fig. 1A-B</xref>; <xref ref-type="supplementary-material" rid="SD1">supplementary file 2</xref>; all screen data are freely accessible at <ext-link ext-link-type="uri" xlink:href="https://www.leishbaseeditdb.net/">www.LeishBASEeditDB.net</ext-link>).</p><p id="P8">To identify drug resistance and sensitivity biomarkers, we screened this library against four clinically important anti-leishmanials, potassium antimony(III) tartrate (Sb<sup>III</sup>, the active form of antimonials), amphotericin B (AmB), miltefosine (MTF), and pentamidine isethionate (PTM), as well as the experimental arylmethylaminosteroid 1c (<xref ref-type="bibr" rid="R60">60</xref>) (<xref ref-type="fig" rid="F1">fig. 1B</xref>). Additionally, we evaluated the functionality of our CBE library by assessing promastigote fitness and motility phenotypes (<xref ref-type="fig" rid="F1">fig. 1B</xref>). Changes in sgRNA abundance were quantified via next-generation sequencing (<xref ref-type="supplementary-material" rid="SD2">fig. S1</xref>) and we detected significant depletions or enrichments in targeting sgRNAs relative to non-targeting controls across all screens (<xref ref-type="supplementary-material" rid="SD2">fig. S2A-H</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 3</xref>), validating the system’s ability to detect functional genomic effects at scale. Median enrichment analysis per gene (<xref ref-type="supplementary-material" rid="SD1">supplementary file 4</xref>) revealed that following 360 hours of promastigote culture ~10% (740) of targeted genes were significantly depleted, indicating loss-of-fitness phenotypes, while ~1% (93 genes) were enriched, suggesting increased fitness. No non-targeting controls were significantly affected (<xref ref-type="fig" rid="F1">fig. 1C</xref>).</p><p id="P9">To confirm the biological relevance of the detected phenotypes, we examined the enrichment of Gene Ontology (GO) terms previously linked to essential functions. We found genes associated with “Intraciliary Transport Particle” (IFT), “Protein Kinase Activity,” “Ribosome” (<xref ref-type="fig" rid="F1">fig. 1D-F</xref>), and especially translational activity (<xref ref-type="fig" rid="F1">fig. 1M</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 5</xref>) to be essential for promastigote survival. These included well-characterized fitness-associated genes like IFT140 (LmxM.31.0310), IFT139 (LmxM.04.0550), CRK2 (LmxM.05.0550), AUK1/AIRK (LmxM.28.0520), and CK1.2 (LmxM.34.1010) (<xref ref-type="fig" rid="F1">fig. 1D-E</xref>) (<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R61">61</xref>–<xref ref-type="bibr" rid="R67">67</xref>). Our library also effectively targeted multi-copy genes using overlapping sgRNA sets. Alpha- (LmxM.13.0280-0300) and beta-tubulin (LmxM.08.1171, LmxM.08.1230, LmxM.21.1860, LmxM.32.0792 &amp; LmxM.32.0794), histone H3 (LmxM.10.0870, LmxM.10.0970, LmxM.10.0990 &amp; LmxM.16.0570-0610), and eIF1α (LmxM.17.0080-0086), all present in dispersed copies or tandem repeats, were significantly depleted, consistent with their expected essential roles (<xref ref-type="fig" rid="F1">fig. 1G</xref>) (<xref ref-type="bibr" rid="R68">68</xref>–<xref ref-type="bibr" rid="R71">71</xref>). Targeting the ABCG1-3 array (LmxM.06.0080–0100) or just ABCG1&amp;2 also produced a gain-of-fitness phenotype, demonstrating resolution of isoform-specific effects (<xref ref-type="fig" rid="F1">fig. 1G</xref>). To validate further screen results, we also individually deleted six genes using Cas12a-mediated gene replacement (<xref ref-type="supplementary-material" rid="SD2">fig. S3</xref>). Measured doubling times of these mutants correlated with their enrichments or depletions in the screen (<xref ref-type="fig" rid="F1">fig. 1H-L</xref>), confirming functional relevance.</p><p id="P10">Given that IFT proteins are essential for flagellar assembly in <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R64">64</xref>–<xref ref-type="bibr" rid="R67">67</xref>), we tested whether our screen could also resolve motility phenotypes. Subjecting the library to a 6-hour transwell assay (<xref ref-type="fig" rid="F1">fig. 1B</xref>), we observed strong depletion of IFT-targeting sgRNAs in the upper chamber and enrichment of non-targeting controls, confirming clear discrimination between motile and non-motile cells (<xref ref-type="fig" rid="F1">fig. 1N</xref>).</p><p id="P11">Overall, this shows that our library detects diverse phenotypes without additional selective pressure. Therefore, we next designed a screening strategy to identify genes linked to both drug resistance and sensitivity. Using calibrated concentrations to synchronize timelines across all compound screens (<xref ref-type="supplementary-material" rid="SD2">fig. S4</xref>), parasites were treated with each drug for 48 hours, followed by two rounds of recovery without drugs (<xref ref-type="fig" rid="F1">fig. 1B</xref>), which confirmed enrichment specificity and revealed residual growth defects.</p></sec><sec id="S4"><title>Flagellar Integrity and Formation Defects Confer Resistance to SB<sup>III</sup> and 1C</title><p id="P12">First, we analyzed Sb<sup>III</sup>-treated fractions, comparing gene enrichment between recovery fractions and their viability screen counterparts (192h vs. recovery 1, 264h vs. recovery 2; <xref ref-type="fig" rid="F1">fig. 1B</xref>). Genes required for flagellar formation, particularly those involved in intraciliary transport (<xref ref-type="fig" rid="F1">fig. 1D, 1N</xref>), were highly associated with Sb<sup>III</sup> resistance (<xref ref-type="fig" rid="F2">fig. 2A</xref>), reinforcing previous indications that a STOP codon insertion in an IFT gene could contribute to resistance (<xref ref-type="bibr" rid="R72">72</xref>). Looking for potential IFT regulators, we also found the sgRNA set targeting BBS9 (LmxM.31.1240) to be enriched in both recoveries (<xref ref-type="fig" rid="F2">fig. 2A</xref>), prompting us to delete all core BBSome components individually (<xref ref-type="supplementary-material" rid="SD2">fig. S3</xref>). Results confirmed that only BBS9 and slow-growing IFT140 (LmxM.31.0310) mutants (<xref ref-type="fig" rid="F1">fig. 1L</xref>) conferred resistance, while addbacks and other BBSome deletions (BBSome (BBS1 [LmxM.34.4180], BBS2 [LmxM.29.0590], BBS4 [LmxM.36.2280], BBS5 [LmxM.12.0680], BBS7 [LmxM.08_29.0710], BBS8 [LmxM.09.0440], BBS18 [LmxM.14.0200] (<xref ref-type="bibr" rid="R73">73</xref>)) did not yield resistance (<xref ref-type="fig" rid="F3">fig. 3A</xref>). These findings align with studies implicating IFTs and the BBSome in drug resistance in <italic>C. elegans</italic> (<xref ref-type="bibr" rid="R74">74</xref>, <xref ref-type="bibr" rid="R75">75</xref>) and support an essential role of BBS9 in BBSome assembly and function (<xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R76">76</xref>) in <italic>Leishmania</italic>. Given that IFT140 (LmxM.31.0310) deletion disrupts flagellar pocket morphology in <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R67">67</xref>), the site of all endo- and exocytosis (<xref ref-type="bibr" rid="R77">77</xref>, <xref ref-type="bibr" rid="R78">78</xref>), we next tested whether genes involved in pocket function, such as those associated with the flagellar attachment zone (FAZ) or vesicle trafficking (e.g., SNAREs, Rabs, VPS), might also confer resistance. However, targeting FAZ genes (<xref ref-type="bibr" rid="R79">79</xref>) or vesicle-related genes (<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R81">81</xref>) did not result in notable Sb<sup>III</sup> resistance, except for minor effects with Rab5a (LmxM.18.1130) and Rab6 (LmxM.02.0260) (<xref ref-type="supplementary-material" rid="SD2">fig. S5</xref>).</p><p id="P13">Instead, resistance appeared to correlate more directly with flagellar integrity. Deletion of Arl6/BBS3 (LmxM.16.1380), a BBSome-associated but non-core component localized to the flagellum (<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R83">83</xref>), also increased Sb<sup>III</sup> tolerance (<xref ref-type="fig" rid="F3">fig. 3A</xref>). Additional resistance-linked genes included flagellar-localized proteins UBC2 (LmxM.04.0680), MRK1 (LmxM.31.0120), and PP2C (LmxM.25.0750) (<xref ref-type="supplementary-material" rid="SD2">fig. S6A</xref>), as well as basal flagellar proteins LmxM.19.0450 (<xref ref-type="bibr" rid="R84">84</xref>), NPHP4 (LmxM.25.2000) (<xref ref-type="bibr" rid="R85">85</xref>), and FOPNL (LmxM.32.1895) (<xref ref-type="bibr" rid="R86">86</xref>) (<xref ref-type="fig" rid="F2">fig. 2A</xref>). Finally, we identified the glucose transporters LMGT1–3 (LmxM.36.6280-6300), of which LMGT1 (LmxM.36.6300) localizes to the flagellum (<xref ref-type="bibr" rid="R87">87</xref>), as mediators of Sb<sup>III</sup> resistance, specifically when sgRNA sets targeted either all three isoforms or both LMGT1 and LMGT2 (LmxM.36.6290) (<xref ref-type="fig" rid="F2">fig. 2A</xref>). Since FOPNL (LmxM.32.1895) (<xref ref-type="bibr" rid="R86">86</xref>), NPHP4 (LmxM.25.2000) (<xref ref-type="bibr" rid="R85">85</xref>), BBS9 (LmxM.31.1240) (<xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R76">76</xref>) and IFTs (<xref ref-type="bibr" rid="R88">88</xref>) are known regulators of flagellar/ciliary trafficking in other systems, our findings support a model in which Sb<sup>III</sup> influx is mediated via the flagellum, similar to drug uptake mechanisms recently proposed in <italic>C. elegans</italic> (<xref ref-type="bibr" rid="R74">74</xref>, <xref ref-type="bibr" rid="R75">75</xref>). This also aligns with earlier suggestions of diverse flagellar functions in <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R90">90</xref>).</p><p id="P14">However, not all enriched genes were flagellum-associated. We also identified ZF-CCCH (LmxM.15.0160), a known Sb<sup>III</sup> target (<xref ref-type="bibr" rid="R91">91</xref>, <xref ref-type="bibr" rid="R92">92</xref>), and DUB22 (LmxM.34.1390), a putative OTU-like cysteine protease with a Zn-finger domain (<xref ref-type="fig" rid="F2">fig. 2A</xref>, <xref ref-type="fig" rid="F3">3A</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Interestingly, AQP1 (LmxM.30.0020), another flagellar-localized membrane protein (<xref ref-type="bibr" rid="R93">93</xref>), did not significantly confer Sb<sup>III</sup> resistance in our screen (<xref ref-type="fig" rid="F2">fig. 2A</xref>) or when deleted individually (<xref ref-type="fig" rid="F3">fig. 3A</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>), despite prior reports of AQP1-linked resistance in <italic>L. major</italic> through single allele mutation (<xref ref-type="bibr" rid="R14">14</xref>), full gene disruption (<xref ref-type="bibr" rid="R18">18</xref>), and studies in other <italic>Leishmania</italic> species (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>). Given that a parallel CBE Sb<sup>III</sup> resistance screen in <italic>L. major</italic> performed by our group identified AQP1 as strong resistance factor (data not shown), our findings suggest species-specific differences in Sb<sup>III</sup> resistance, a phenomenon previously observed (<xref ref-type="bibr" rid="R16">16</xref>) and further explored in another forthcoming study (Beneke lab, unpublished).</p><p id="P15">Interestingly, IFTs, UBC2 (LmxM.04.0680), NPHP4 (LmxM.25.2000), and FOPNL (LmxM.32.1895) were also enriched following 1c treatment (<xref ref-type="fig" rid="F2">fig. 2B</xref>), reinforcing a link between drug resistance and flagellar-mediated drug uptake. Individual deletions (<xref ref-type="fig" rid="F3">fig. 3B</xref> &amp; <xref ref-type="supplementary-material" rid="SD2">S3</xref>) and the screen also showed that mutations in MKK1 (LmxM.08_29.2320) and MPK3 (LmxM.10.0490), either alone or in combination, conferred 1c resistance, consistent with their role in flagellar length maintenance (<xref ref-type="supplementary-material" rid="SD2">fig. S6B-C</xref>) within a shared signalling cascade (<xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R95">95</xref>) (<xref ref-type="supplementary-material" rid="SD2">fig. S6B</xref>). Additionally, 1c resistance was observed upon targeting another protein kinase (PK, LmxM.02.0570) and an uncharacterized protein, LmxM.10.0940, here named CRM143 (1c resistance marker of 143 kDa) (<xref ref-type="fig" rid="F2">fig. 2B</xref>, <xref ref-type="fig" rid="F3">3B</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Conversely, LmxM.20.0690, designated CSM142 (1c sensitivity marker of 142 kDa), increased 1c sensitivity in both individual tests and the screen (<xref ref-type="fig" rid="F2">fig. 2B</xref>, <xref ref-type="fig" rid="F3">3B</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Together, these findings reveal both drug-specific and shared resistance mechanisms for Sb<sup>III</sup> and 1c, particularly involving flagellar-associated pathways.</p></sec><sec id="S5"><title>Sterol Metabolism and Transporter Function Shape AMB and MTF Response</title><p id="P16">A similar pattern of partial overlap and drug-specific mechanisms was also observed between AmB and MTF resistance. As previously reported, mutations in genes involved in sterol biosynthesis conferred AmB resistance (<xref ref-type="bibr" rid="R28">28</xref>–<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R39">39</xref>). Notably, we observed strong enrichment for loss-of-function mutations in the lathosterol oxidase-like protein (LSO-like) ERG3 (LmxM.23.1300) and the Lanosterol 14-alpha demethylase (LS14αD) ERG11 (LmxM.11.1100) (<xref ref-type="fig" rid="F2">fig. 2C, 2F</xref>), both critical for synthesizing ergosterol and related sterols (<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R39">39</xref>). In addition, targeting of P450R1 (LmxM.28.1240) conferred strong AmB and mild MTF resistance in both the screen and individual deletions (<xref ref-type="fig" rid="F2">fig. 2C, 2D</xref>, <xref ref-type="fig" rid="F3">3C, 3E</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). The AmB resistance is consistent with recent findings showing that P450R1 mutants lack ergosterol and accumulate 14-methylfecosterol and related intermediates (<xref ref-type="bibr" rid="R36">36</xref>), while the MTF resistance, though previously unreported, aligns with earlier suggestions linking MTF resistance to disruptions in lipid and sterol metabolism (<xref ref-type="bibr" rid="R40">40</xref>).</p><p id="P17">By contrast, ERG2 (LmxM.08_29.2140) showed only mild enrichment with AmB, and other sterol-related genes like ERG4 (LmxM.32.0680), ERG5 (LmxM.29.3550), ERG7 (LmxM.06.0650) and ERG24 (LmxM.31.2320) were not significantly enriched (<xref ref-type="fig" rid="F2">fig. 2C, 2F</xref>). We also identified two hypothetical small proteins, ABRM7 (LmxM.25.2375) and ABRM8 (LmxM.34.0270) (AmB resistance marker of 7 and 8 kDa), that conferred AmB resistance in individual deletions and the screen (<xref ref-type="fig" rid="F2">fig. 2C</xref>, <xref ref-type="fig" rid="F3">3C</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Both proteins are conserved across the Trypanosomatidae family, with no homologs detected outside this lineage. Sterol profiling of their null mutants revealed a complete loss of 5-dehydro-episterol and lanosterol, alongside increased C28- and C29-diene-sterol-3 levels (<xref ref-type="supplementary-material" rid="SD2">fig. S7A-D</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 6</xref>), suggesting a possible regulatory role in ERG3 (LmxM.23.1300) activity (<xref ref-type="fig" rid="F2">fig. 2F</xref>).</p><p id="P18">Finally, we identified three transmembrane proteins enriched in AmB-resistant fractions (<xref ref-type="fig" rid="F2">fig. 2C</xref>), all of which also conferred strong MTF resistance (<xref ref-type="fig" rid="F2">fig. 2D</xref>) with comparable EC<sub>50</sub> shifts (<xref ref-type="fig" rid="F3">fig. 3E</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Two correspond to known MTF resistance markers, LEM3/ROS3 (LmxM.31.0510) and LMT (LmxM.13.1530), which together form the MTF transporter complex (<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R27">27</xref>). The third is a previously uncharacterized, small hypothetical protein we designate LMT17 (<italic>Leishmania</italic> MTF transporter of 17 kDa; LmxM.06.0995) (<xref ref-type="fig" rid="F2">fig. 2C-D</xref>, <xref ref-type="fig" rid="F3">3C, 3E</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>), whose presence was later shown to be essential for proper localization of the MTF transporter complex, indicating its role as a previously unrecognized MTF-complex component (<xref ref-type="supplementary-material" rid="SD2">fig. S8-S10</xref>). While earlier reports placed LMT (LmxM.13.1530) at the plasma membrane (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R27">27</xref>), we consistently observed two distinct intracellular signals, likely corresponding to the Golgi apparatus and multivesicular tubule (MVT) lysosome. This tubulovesicular localization resembled that reported for other resistance markers such as PRP1 (<xref ref-type="bibr" rid="R96">96</xref>), MRPA (<xref ref-type="bibr" rid="R97">97</xref>), and MDR1 (<xref ref-type="bibr" rid="R98">98</xref>). Observed across multiple C-terminal tags (mNeonGreen (mNG), eYFP, Myc, HA, mCherry (mCh); <xref ref-type="supplementary-material" rid="SD2">fig. S8</xref>, S9, S10D), this pattern suggests that LMT may actually function within the exocytic and endocytic pathways (<xref ref-type="bibr" rid="R99">99</xref>). Importantly, tagging both LMT (LmxM.13.1530) alleles with mNG and mCh did not significantly increase MTF resistance (<xref ref-type="supplementary-material" rid="SD2">fig. S10A</xref>-D), indicating that the tag did not disrupt function. However, the MTF localization signal was lost upon deletion of either LEM3/ROS3 (LmxM.31.0510) or LMT17 (LmxM.06.0995), and was fully or partially restored by episomal complementation (<xref ref-type="supplementary-material" rid="SD2">fig. S10E-G</xref>). While the localization dependency of LMT (LmxM.13.1530) and LEM3/ROS3 (LmxM.31.0510) has been previously shown (<xref ref-type="bibr" rid="R23">23</xref>), our findings identify LMT17 (LmxM.06.0995) as an additional requirement, supporting its role as a novel component of the MTF transporter complex.</p><p id="P19">In addition to LMT-related components, we identified several other genes associated with MTF insensitivity (<xref ref-type="fig" rid="F2">fig. 2D</xref>). Two of these, MRM202 (LmxM.09.0390) and MRM21 (LmxM.31.3830) (MTF resistance marker of 202 kDa and 21 kDa), conferred relatively strong resistance both in the screen and when subject to individual deletions (<xref ref-type="fig" rid="F2">fig. 2D</xref>, <xref ref-type="fig" rid="F3">3E</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). In contrast, ABCT (LmxM.15.0890) showed no resistance and MRM354 (MTF resistance marker of 354 kDa, LmxM.24.0260) even increased susceptibility when mutated individually (<xref ref-type="fig" rid="F3">fig. 3E</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>), despite being enriched over the screen (<xref ref-type="fig" rid="F2">fig. 2D</xref>). Growth analysis revealed significantly reduced doubling times in both the screen (<xref ref-type="fig" rid="F1">fig. 1J-K</xref>) and individual knockouts (<xref ref-type="fig" rid="F1">fig. 1L</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Further validation then confirmed that their insensitivity and enrichment was due to selective recovery after treatment rather than true resistance during drug exposure (<xref ref-type="fig" rid="F3">fig. 3F</xref>). Since none of the other 91 sgRNA sets associated with faster growth (<xref ref-type="fig" rid="F1">fig. 1C</xref>) were enriched after MTF or any other anti-leishmanial drug treatment (<xref ref-type="fig" rid="F2">fig. 2A</xref>-E), these findings suggest that mutations in ABCT (LmxM.15.0890) and MRM354 (LmxM.24.0260) enhance MTF-specific post-treatment recovery rather than confer direct resistance, an effect that may be clinically significant given the high relapse rates observed after MTF monotherapy (<xref ref-type="bibr" rid="R100">100</xref>).</p></sec><sec id="S6"><title>Sterol and Sphingolipid Balance Controls PTM and AMB Susceptibility</title><p id="P20">Membrane composition also appeared to influence PTM resistance, but via a distinct mechanism. Here, resistance emerged through disruption of numerous different sphingolipid metabolism genes, including DHCS (LmxM.30.1780), SPT (LmxM.34.0320), SPT-like (LmxM.33.3740), SLS3 (LmxM.34.4990), EPT (LmxM.18.0810), and others (<xref ref-type="fig" rid="F2">fig. 2E, G</xref>). Individual deletion of several of these genes (<xref ref-type="supplementary-material" rid="SD2">fig. S3</xref>) resulted in increased doubling times (<xref ref-type="fig" rid="F1">fig. 1H, 1L</xref>, <xref ref-type="supplementary-material" rid="SD2">S11A</xref>), and cell-counting assays confirmed strong PTM resistance (<xref ref-type="fig" rid="F3">fig. 3H</xref>), consistent with the screen (<xref ref-type="fig" rid="F2">fig. 2E</xref>). However, standard EC<sub>50</sub> determination using MTT (Thiazolyl Blue Tetrazolium Bromide), as applied to other mutants (<xref ref-type="fig" rid="F3">fig. 3A-C, 3E, 3G</xref>), was not feasible for several PTM-resistant lines due to poor tetrazolium dye conversion (<xref ref-type="supplementary-material" rid="SD2">fig. S11B</xref>). Although this was not observed in all sphingolipid-defective mutants (<xref ref-type="fig" rid="F2">fig. 2E, 2G</xref>, <xref ref-type="supplementary-material" rid="SD2">S11B</xref>), this impairment likely reflects disrupted mitochondrial function and redox activity, as previously reported for sphingolipid metabolism mutants (<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R101">101</xref>–<xref ref-type="bibr" rid="R106">106</xref>), and aligns with mitochondrial exclusion as a known mechanism of PTM resistance in <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R107">107</xref>, <xref ref-type="bibr" rid="R108">108</xref>).</p><p id="P21">Beyond sphingolipid metabolism, our screen and individual validations identified diverse PTM resistance markers (<xref ref-type="fig" rid="F2">fig. 2E</xref>, <xref ref-type="fig" rid="F3">3H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). These included membrane-associated proteins, including a putative major facilitator superfamily (MFS) transporter (LmxM.22.1050) and a calcium-motive P-type ATPase (PMCA, LmxM.34.2080), as well as components of retrograde Golgi-to-ER transport and ER membrane protein retention (COPE, LmxM.31.1730; RER1, LmxM.22.0580). We also found post-translational regulators, including a ubiquitin-conjugating enzyme-like protein (UBC-like, LmxM.21.0440) and DUB22 (LmxM.34.1390), which also conferred Sb<sup>III</sup> resistance (<xref ref-type="fig" rid="F2">fig. 2A, 2E</xref>, <xref ref-type="fig" rid="F3">3A, 3H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). Additional markers included an annotated adenylate kinase (ADK, LmxM.04.0960) and two hypothetical proteins, here named PRM11 (LmxM.33.3955) and PRM60 (LmxM.27.1140) (PTM resistance markers of 11 and 60 kDa) (<xref ref-type="fig" rid="F2">fig. 2E</xref>, <xref ref-type="fig" rid="F3">3H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>).</p><p id="P22">Lipidomic profiling (<xref ref-type="supplementary-material" rid="SD2">fig. S7E</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 7</xref>) of selected mutants revealed that DHCS (LmxM.30.1780) and SPT-like (LmxM.33.3740) null mutants exhibited the anticipated (<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R101">101</xref>–<xref ref-type="bibr" rid="R105">105</xref>) alterations in sphingo-, phospho-, and glycerol-lipid biosynthesis, whereas the ADK (LmxM.04.0960) mutant showed milder shifts limited to phospho- and glycerol-lipids. Notably, lipid changes were minimal in the PRM11 (LmxM.33.3955) null mutant (<xref ref-type="supplementary-material" rid="SD2">fig. S7E</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 7</xref>), suggesting that altered lipid composition contributes to PTM resistance, but does not universally explain it.</p><p id="P23">Interestingly, functional mutations in sphingolipid metabolism genes that conferred PTM resistance, such as DHCS (LmxM.30.1780), SPT (LmxM.34.0320), SPT-like (LmxM.33.3740), SLS3 (LmxM.34.4990), and EPT (LmxM.18.0810), also increased sensitivity to AmB (<xref ref-type="fig" rid="F2">fig. 2C, 2E</xref>, <xref ref-type="fig" rid="F3">3D, 3H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>), despite largely unchanged sterol profiles (<xref ref-type="supplementary-material" rid="SD2">fig. S7E</xref>, <xref ref-type="supplementary-material" rid="SD1">supplementary file 7</xref>). This mirrors earlier findings, where disruption of sphingolipid and ceramide biosynthesis compromised protection against ergosterol-binding toxins, thereby increasing AmB sensitivity (<xref ref-type="bibr" rid="R109">109</xref>). Conversely, mutations in sterol biosynthesis genes, like ABRM7 (LmxM.25.2375), ABRM8 (LmxM.34.0270), and ERG3 (LmxM.23.1300), conferred AmB resistance but increased PTM susceptibility (<xref ref-type="fig" rid="F2">fig. 2C, 2E</xref>, <xref ref-type="fig" rid="F3">3C, 3G</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>), consistent with previous reports of sterol mutants exhibiting heightened PTM sensitivity (<xref ref-type="bibr" rid="R37">37</xref>). These findings support a compensatory mechanism in <italic>Leishmania</italic>, whereby perturbation of either sterol or sphingolipid pathways enhances resistance to one drug while sensitizing the parasite to the other. Although this reciprocal resistance and sensitivity pattern may seem coincidental, it likely reflects distinct mechanisms. Elevated mitochondrial membrane potential has been observed in LS14αD ERG11 (LmjF.11.1100) <italic>L. major</italic> null mutants (<xref ref-type="bibr" rid="R110">110</xref>), suggesting that sterol loss increases PTM sensitivity by promoting its uptake into mitochondria. This is consistent with the mitochondrial exclusion mechanism of PTM resistance noted above (<xref ref-type="bibr" rid="R107">107</xref>, <xref ref-type="bibr" rid="R108">108</xref>). Conversely, sphingolipid loss may expose ergosterol to AmB, thereby enhancing AmB sensitivity.</p></sec><sec id="S7"><title>Collateral Sensitivities and Opposing Drug Responses Among Paralogs</title><p id="P24">This collateral sensitivity-like mechanism extended beyond mutations in sphingolipid and sterol metabolism genes (<xref ref-type="fig" rid="F2">fig. 2C, 2E</xref>, <xref ref-type="fig" rid="F3">3C-D, 3G-H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3, 4</xref>), as we identified additional resistance markers, including multi-copy genes, that conferred resistance to one drug while increasing sensitivity to another (<xref ref-type="fig" rid="F4">fig. 4</xref>). For example, targeting MRM354 (LmxM.24.0260) and MRM202 (LmxM.09.0390), two uncharacterized genes without annotated domains, conferred MTF resistance and Sb<sup>III</sup> sensitivity (<xref ref-type="fig" rid="F2">fig. 2A, 2D</xref>), along with accelerated growth phenotypes (<xref ref-type="fig" rid="F1">fig. 1L</xref>, <xref ref-type="fig" rid="F4">4</xref>). While no reduced doubling time was observed for markers of Sb<sup>III</sup>, 1c, or AmB response, faster growth was also seen upon targeting ABCT (LmxM.15.0890) (<xref ref-type="fig" rid="F1">fig. 1K-L</xref>, <xref ref-type="fig" rid="F4">4</xref>), which conferred MTF tolerance (<xref ref-type="fig" rid="F2">fig. 2D</xref>, <xref ref-type="fig" rid="F3">3F</xref>, <xref ref-type="fig" rid="F4">4</xref>), and increased sensitivity to Sb<sup>III</sup> and AmB (<xref ref-type="fig" rid="F2">fig. 2A, 2C</xref>, <xref ref-type="fig" rid="F3">3A, 3C</xref>, <xref ref-type="fig" rid="F4">4</xref>).</p><p id="P25">Although the sgRNA set uniquely targeted ABCT (LmxM.15.0890), we identified five additional paralogs in the <italic>L. mexicana</italic> genome. Two (LmxM.23.0380, LmxM.36.2890) were targeted independently and showed no phenotype. In contrast, a shared sgRNA set targeting all tandem-arrayed ABCG1-3 isoforms (ABCG1: LmxM.06.0080; ABCG2: LmxM.06.0090; ABCG3: LmxM.06.0100) yielded a similar pattern to ABCT (LmxM.15.0890), including reduced doubling time (<xref ref-type="fig" rid="F1">fig. 1G</xref>, <xref ref-type="fig" rid="F4">4</xref>), increased MTF resistance (although only with few sgRNAs, <xref ref-type="supplementary-material" rid="SD2">fig. S12</xref>), and heightened Sb<sup>III</sup> and AmB sensitivity (<xref ref-type="fig" rid="F4">fig. 4</xref>, <xref ref-type="supplementary-material" rid="SD2">S12</xref>). As ABC subfamily G transporters are linked to lipid trafficking and resistance (<xref ref-type="bibr" rid="R111">111</xref>–<xref ref-type="bibr" rid="R113">113</xref>), their disruption may impair lipid export, altering membrane composition and promoting sterol accumulation. This may increase Sb<sup>III</sup> and AmB susceptibility while enhancing MTF tolerance.</p><p id="P26">Conversely to these classical collateral sensitivity mechanisms, we also identified opposing drug responses among paralogous genes for the same compound. For example, ABCC1 (LmxM.23.0210), conferred resistance to PTM (<xref ref-type="fig" rid="F2">fig. 2E</xref>) and is part of a larger gene family with seven paralogs. Five of these form two tandem arrays: LmxM.23.0210–0220 and LmxM.30.1270–1290. sgRNA sets targeting ABCC1 alone or the first tandem repeat yielded increased PTM resistance (<xref ref-type="fig" rid="F2">fig. 2E</xref>), whereas targeting the second repeat had no impact. Intriguingly, the seventh paralog, a p-glycoprotein-like gene (pGP-like; LmxM.30.1430), showed the opposite phenotype: its disruption led to PTM hypersensitivity, both in the screen and in individual mutants (<xref ref-type="fig" rid="F2">fig. 2E</xref>, <xref ref-type="fig" rid="F3">3H</xref>, <xref ref-type="supplementary-material" rid="SD2">S3</xref>). These findings are consistent with previous reports of ABCC1 mediating PTM sequestration (<xref ref-type="bibr" rid="R96">96</xref>, <xref ref-type="bibr" rid="R114">114</xref>) and P-glycoproteins functioning as efflux pumps (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R115">115</xref>–<xref ref-type="bibr" rid="R117">117</xref>).</p></sec></sec><sec id="S8" sec-type="discussion"><title>Discussion</title><p id="P27">Here, we successfully established a CBE loss-of-function screen in <italic>L. mexicana</italic>, targeting 94% of the protein-coding genome to systematically dissect the genetic determinants of drug response and fitness in promastigotes. This genome-wide approach enabled the identification of several known and numerous previously unrecognized resistance and sensitivity biomarkers, including evidence for a flagellar-mediated drug uptake mechanism. Functional characterization revealed roles for previously unknown genes, including ABRM7 (LmxM.25.2375) and ABRM8 (LmxM.34.0270) in sterol biosynthesis, and LMT17 (LmxM.06.0995) in regulating the localization of the MTF transporter complex, which we show here to be part of the endo- and exocytic system. Our data uncovered collateral sensitivities and opposing drug responses in mutants of genes involved in sphingolipid and sterol metabolism, ABC transporters (ABCT, LmxM.15.0890; ABCG1–3, LmxM.06.0080–0100; ABCC1, LmxM.23.0210–0220; pGP-like, LmxM.30.1430), and uncharacterized loci (MRM354, LmxM.24.0260; MRM202, LmxM.09.0390) (<xref ref-type="fig" rid="F4">fig. 4</xref>). We also identified cross-resistance cases: DUB22 (LmxM.34.1390) with Sb<sup>III</sup> and PTM; IFTs and other flagellar-associated genes (FOPNL, LmxM.32.1895; NPHP4, LmxM.25.2000; UBC2, LmxM.04.0680) with Sb<sup>III</sup> and 1c; and P450R1 (LmxM.28.1240), LMT (LmxM.13.1530), and LMT17 (LmxM.06.0995) with AmB and MTF. Our findings in <italic>L. mexicana</italic>, a genetically tractable model, support rational combination therapy design and are likely to translate across <italic>Leishmania</italic> species, despite some physiological differences, such as the apparent lack of AQP1 (LmxM.30.0020) involvement in Sb<sup>III</sup> uptake in <italic>L. mexicana</italic>. Regimens like AmB+PTM or MTF+Sb<sup>III</sup> may be beneficial, whereas AmB+MTF, Sb<sup>III</sup>+PTM, and Sb<sup>III</sup>+1c should be avoided due to shared resistance profiles.</p><p id="P28">This is clinically relevant given the current use of MTF and AmB combinations, where emerging cross-resistance could undermine efficacy (<xref ref-type="bibr" rid="R118">118</xref>). Prior work has shown that combination resistance can be induced and may enhance parasite fitness (<xref ref-type="bibr" rid="R119">119</xref>, <xref ref-type="bibr" rid="R120">120</xref>). This aligns with the increased fitness we observed in MTF-resistant mutants like MRM202 (LmxM.09.0390), ABCT (LmxM.15.0890) and MRM354 (LmxM.24.0260) (<xref ref-type="fig" rid="F4">fig. 4</xref>). Additionally, ABCT and MRM354 showed rapid post-treatment recovery without direct resistance, suggesting a persister-like phenotype (<xref ref-type="fig" rid="F3">fig. 3F</xref>), consistent with dormant survival proposed for <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R121">121</xref>). Such behaviour may underlie high relapse rates seen after MTF monotherapy (<xref ref-type="bibr" rid="R100">100</xref>), underscoring the clinical relevance of these biomarkers.</p><p id="P29">The persister-like phenotype of ABCT (LmxM.15.0890) likely extends beyond promastigotes, as ABCT mutants were also enriched during mouse infections in a recent bar-seq study (<xref ref-type="bibr" rid="R122">122</xref>). Several additional resistance markers identified in our study are also likely relevant in intracellular amastigotes without compromising fitness. For instance, sphingolipid-deficient parasites remain infectious by salvaging host lipid precursors (<xref ref-type="bibr" rid="R123">123</xref>–<xref ref-type="bibr" rid="R126">126</xref>). Similarly, some markers show no detectable amastigote phenotype, including the 1c-resistant PK (LmxM.02.0570), PTM-resistant MFS transporter (LmxM.22.1050), and MTF-resistant LMT (LmxM.13.1530) (<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R127">127</xref>). Conflicting reports exist for sterol biosynthesis mutants, including AmB-resistant strains, which display variable infectivity as some remain infectious while others show loss of infectivity (<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R39">39</xref>). By contrast, functional mutations in some resistance genes, such as P450R1 (LmxM.28.1240) (<xref ref-type="bibr" rid="R36">36</xref>) and those involved in flagellar formation (MRK1, LmxM.31.0120; MKK1, LmxM.08_29.2320; MPK3, LmxM.10.0490; BBS9, LmxM.31.1240; IFTs), are known to impact amastigote growth and therefore are less likely to contribute to clinical resistance (<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R66">66</xref>, <xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R95">95</xref>, <xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R128">128</xref>). Still, flagellar-defective parasites have been isolated from patients (<xref ref-type="bibr" rid="R129">129</xref>), so their relevance cannot be fully excluded, underscoring the need for further investigation in the amastigote stage and across <italic>Leishmania</italic> species.</p><p id="P30">We therefore now aim to apply our genome-wide CBE libraries to study drug responses in intracellular amastigotes, enabling the discovery of stage- and species-specific resistance markers, similar to prior cosmid-based screens (<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R130">130</xref>). These forthcoming efforts will also address current limitations, such as unintended non-deleterious deletions or truncation mutations, by incorporating guide activity reporters to evaluate base editing efficiency (<xref ref-type="bibr" rid="R131">131</xref>). Our current screen thus provides a versatile framework for dissecting single- and multi-gene functions and serves as a proof-of-concept for genome-scale functional screening in <italic>Leishmania</italic> and perhaps other parasites lacking RNAi and non-homologous end-joining pathways.</p></sec><sec id="S9" sec-type="materials | methods"><title>Material and Methods</title><sec id="S10"><title>Cell culture and parasite strain</title><p id="P31"><italic>L. mexicana</italic> (WHO strain MNYC/BZ/62/M379) promastigotes were cultured at 28°C in M199 medium (Invitrogen, cat. no. 31100-019) supplemented with 2.2 g/L NaHCO<sub>3</sub>, 0.0025% hemin, 0.1 mM adenine hemisulfate, 1.2 µg/mL 6-biopterin, 40 mM HEPES (pH 7.4), and 20% heat-inactivated fetal calf serum (FCS; Invitrogen, cat. no. 10500064). If required, culture media were further supplemented with 40 µg/mL of each appropriate selection antibiotic: Hygromycin B, Puromycin Dihydrochloride, Blasticidin S Hydrochloride, Phleomycin, and G-418 Disulfate (all sourced from InvivoGen). Doubling times were determined as described previously (<xref ref-type="bibr" rid="R57">57</xref>).</p><p id="P32">For the genome-wide CRISPR loss-of-function screen and generation of most knockout lines, we used <italic>L. mexicana</italic> constitutively expressing tdTomato from the 18S rRNA SSU locus (<xref ref-type="bibr" rid="R57">57</xref>) and harbouring the pTB107 plasmid for expression of the CBE, Cas12a, and T7 RNA polymerase (<xref ref-type="bibr" rid="R58">58</xref>), hereafter referred to as PARCas12a. This cell line was also employed for single-allele tagging of LMT (LmxM.13.1530) and for dependency assays involving deletions of LEM3/ROS3 (LmxM.31.0510) and LMT17 (LmxM.06.0995).</p><p id="P33">When Cas12a-mediated deletions were unsuccessful (see further details under “Cas9 and Cas12a-mediated gene replacement for generation of knockout and tagging cell lines”), <italic>L. mexicana</italic> harbouring the pTB007 plasmid for expression of Cas9 and T7 RNA polymerase (<xref ref-type="bibr" rid="R132">132</xref>), referred to as PARCas9, was used instead. This Cas9-expressing line was also utilized for tagging of UBC2 (LmxM.04.0680), MRK1 (LmxM.31.0120), PP2C (LmxM.25.0750), and double-allele tagging of LMT (LmxM.13.1530).</p></sec><sec id="S11"><title>CBE sgRNA library design and generation</title><p id="P34">CBE sgRNA sequences for the genome-wide library were obtained from <ext-link ext-link-type="uri" xlink:href="https://www.leishbaseedit.net">www.leishbaseedit.net</ext-link> (<xref ref-type="bibr" rid="R57">57</xref>). For each protein-coding gene in the <italic>L. mexicana</italic> MHOM/GT/2001/U1103 genome (TriTrypDB v59) (<xref ref-type="bibr" rid="R133">133</xref>, <xref ref-type="bibr" rid="R134">134</xref>), all sgRNAs predicted to introduce a STOP codon within the first 50% of the ORF were selected. These were ranked as previously described (<xref ref-type="bibr" rid="R58">58</xref>), and 1-6 top-ranked sgRNAs per gene were chosen, depending on availability.</p><p id="P35">After removing duplicates and sgRNAs containing PacI or BbsI restriction sites, 38,422 unique CBE sgRNAs remained, covering 94% of all protein-coding genes. For the remaining 6% of protein-coding genes, no CBE sgRNA could be designed to introduce a STOP codon within the first 50% of the ORF. Overlapping sgRNAs across geneIDs resulted in 7,378 unique gene targets and 340 multi-gene targets. BLAST analysis further classified the multi-gene targets into 190 multi-copy genes (E-value = 0) and 150 isoforms (E-value &gt; 0). Eighteen sgRNA sets targeting unrelated gene pairs were excluded from downstream analysis. This yielded 7,718 total sgRNA sets. Distribution across these sets was: 6.4% with 1 sgRNA, 7.8% with 2, 6.6% with 3, 6.5% with 4, 6.9% with 5, and 65.8% with 6 sgRNAs, averaging ~5.2 sgRNAs per gene. An additional 1,000 non-targeting sgRNAs (<xref ref-type="bibr" rid="R135">135</xref>) were included as controls. The final 39,422-sgRNA library was synthesized by GenScript and cloned into pTB105, optimized for CBE expression in <italic>Leishmania</italic> (<xref ref-type="bibr" rid="R58">58</xref>).</p></sec><sec id="S12"><title>Transfection of CBE sgRNA expression library and CRISPR screen</title><p id="P36">To transfect the CBE sgRNA expression library into <italic>L. mexicana</italic>, we upscaled our previously established Cas12a-based protocol using crRNA-4 to mediate integration into the 18S rRNA SSU locus (<xref ref-type="bibr" rid="R58">58</xref>). For crRNA synthesis, 40 µl each of 100 µM Cas12a common forward primer (5′ gaaattaatacgactcactataggTAATTTCTACTGTCGTAGAT 3′) and crRNA-4 reverse primer (5′ ttccccgtgttgagtcaaatATCTACGACAGTAGAAATTA 3′) were mixed with 420 µl ddH<sub>2</sub>O and 500 µl FastGene Optima HotStart Ready Mix (Nippon), and amplified in a pre-heated thermocycler: 95°C for 3 min, 35 cycles of 95°C for 15 s, 65°C for 15 s, 72°C for 10 s, and final extension at 72°C for 7 min. For CBE sgRNA library preparation, 480 µg of pTB105-cloned CBE sgRNA library was digested with PacI overnight at 37°C across 8 × 300 µl reactions (60 µg DNA/reaction). Cas12a crRNA and digested DNA were verified via agarose gel, ethanol-precipitated, and resuspended in ddH<sub>2</sub>O (crRNA: ~680 µg in 160 µl; linearized library DNA: ~320 µg in 320 µl). Libraries were divided into triplicates (~107 µg library DNA/replicate), and 100 ng was separated for 0h NGS analysis. Then, each replicate was supplemented with 226 µg crRNA.</p><p id="P37">Each triplicate was transfected with 1.5 × 10<sup>9</sup> PBS-washed promastigotes across 15 electroporation cuvettes (~7 µg library DNA, ~15 µg Cas12a crRNA, 1 × 10<sup>8</sup> cells per cuvette, total of 110 µl) using Lonza’s Basic Parasite Nucleofector Kit and program X-001 on an Amaxa Nucleofector 2b (Lonza). Cuvettes were rinsed 4× with medium and pooled into 750 ml/replicate (2 × 10<sup>6</sup> cells/ml). After 12 h, selection was initiated using 50 µg/ml Hygromycin B and 50 µg/ml Puromycin Dihydrochloride. The transfection efficiency was determined as previously described (<xref ref-type="bibr" rid="R57">57</xref>), yielding approximately one transfectant per 70 electroporated cells. This corresponded to a representation rate of ~500 cells per sgRNA within the transfected library. Cultures were maintained with 50 µg/ml Hygromycin B and 50 µg/ml Puromycin Dihydrochloride for 360 h with regular subculturing (<xref ref-type="fig" rid="F1">fig. 1B</xref>) at ≥2 × 10<sup>7</sup> cells to retain coverage.</p><p id="P38">At 144 hours post-transfection, 2 × 10<sup>7</sup> cells per triplicate were placed in the bottom chamber of 4 transwells (24-well insert, 5.0 µm PET clear; cellQart 9325012). After 6 hours of incubation, DNA was extracted from cells that migrated to the upper chamber. In parallel, 2 × 10<sup>7</sup> cells per triplicate were subcultured into 50 mL complete M199 medium and treated with the following concentrations of anti-leishmanial drugs: 5x EC<sub>50</sub> Sb<sup>III</sup> (272µM) (230057-10G Sigma), 3.5x EC<sub>50</sub> AmB (105nM) (A9528-50mg Sigma), 2.5x EC<sub>50</sub> MTF (53.75µM) (M5571-50mg Sigma), 5x EC<sub>50</sub> PTM (3.35µM) (P0547-100mg Sigma) and 10x arylmethylaminosteroid 1c EC<sub>50</sub> (27µM) (<xref ref-type="bibr" rid="R60">60</xref>). At 192 hours post-transfection, drug-treated cells were centrifuged, the supernatant removed, and cell pellets resuspended in drug-free complete medium. After 48 hours of recovery, cells were subcultured again as shown in <xref ref-type="fig" rid="F1">fig. 1B</xref>.</p><p id="P39">For each time point, DNA was extracted from ≥5 × 10<sup>7</sup> cells using either FastGene Blood &amp; Tissue gDNA Extraction Kit (Nippon FG-70250) or DNeasy Blood &amp; Tissue Kit (Qiagen 69504). Then, 2 µg genomic DNA from each time point and 10 ng DNA from plasmid libraries were amplified using FastGene Optima HotStart Ready Mix (Nippon). Amplification employed standard desalted p5 and p7 primers (Sigma, <xref ref-type="supplementary-material" rid="SD1">supplementary file 8</xref>), containing inline and i5/i7 barcodes for multiplexing, as well as adapters for Illumina sequencing. Barcodes had a Hamming distance of at least 4 nt. To avoid over-amplification, samples isolated from transfected populations were amplified using 26 PCR cycles, while plasmid samples were amplified using only 16 PCR cycles (ideal number of PCR cycles was assessed by testing 12, 14, 16, 18 and 20 PCR cycles for plasmid samples and 22, 24, 26, 28, 30 and 32 PCR cycles for samples isolated from transfected cells; <xref ref-type="supplementary-material" rid="SD2">fig. S1B</xref>). Amplicons were pooled in equal ratios, size-selected using SPRIselect beads (Beckman Coulter) and send to Novogene GmbH for partial-lane Illumina sequencing (250 bp paired-end sequencing).</p></sec><sec id="S13"><title>Analysis of CRISPR screening data</title><p id="P40">For CRISPR screening analysis, sequencing reads were de-multiplexed in two steps: first using bcl2fastq (Illumina) with i5/i7 indices, and then using cutadapt (<xref ref-type="bibr" rid="R136">136</xref>) with inline barcodes and a 0.15 error rate. This dual de-multiplexing strategy minimized index hopping. Forward reads were then processed with MAGeCK (<xref ref-type="bibr" rid="R137">137</xref>), where they were counted, normalized, and quality-checked (<xref ref-type="supplementary-material" rid="SD1">supplementary file 2</xref>). Using MAGeCK’s Test function, p-values and fold-changes were calculated for each of the 39,422 CBE sgRNAs across all sample comparisons (<xref ref-type="supplementary-material" rid="SD1">supplementary file 3</xref>). Viability samples from 96h, 144h, 192h, 264h, 312h, and 360h post-transfection were compared to the 0h plasmid reference. Motility screens used the upper transwell fraction vs. the 144h library. Drug screen recoveries were compared with their viability screen counterparts (192h vs. recovery 1, 264h vs. recovery 2) (<xref ref-type="fig" rid="F1">fig. 1B</xref>). To obtain gene-level metrics for each of the 7,718 targets (7,378 unique and 340 multi-gene), the median p-value and fold-change across sgRNAs per unique gene target or multi-gene target were computed (<xref ref-type="supplementary-material" rid="SD1">supplementary file 4</xref>). Gene- and sgRNA-level results from all three replicates were averaged and standard deviations were determined (<xref ref-type="supplementary-material" rid="SD1">supplementary file 3 &amp; 4</xref>). Since the library contained on average 5.2 sgRNAs per unique or multi-gene target, the 1,000 non-targeting controls were grouped randomly into sets of five. While this grouping had little effect on enrichment results (<xref ref-type="supplementary-material" rid="SD2">fig. S2B-H</xref>), it enabled consistent visualization of targeting vs. non-targeting sgRNA set medians without distortion.</p><p id="P41">Depleted and enriched genes were defined using fold-change thresholds of ≤ 0.5 or ≥ 2 (log<sub>2</sub> of ≤−1 or ≥1), respectively, with significance set at p ≤ 0.05 (log<sub>2</sub> of -4.3219). To examine functional patterns of gene essentiality, Gene Ontology (GO) annotations were retrieved for the <italic>L. mexicana</italic> MHOM/GT/2001/U1103 genome (TriTrypDB v59) (<xref ref-type="bibr" rid="R133">133</xref>, <xref ref-type="bibr" rid="R134">134</xref>), yielding 2,242 unique GO terms. Genes without GO annotations were categorized as “Unclassified.” For GO term ranking, only families with at least 10 genes were included, and gene depletion was assessed at six time points (96, 144, 192, 264, 312, and 360 h post-transfection). For each GO family, the proportion of depleted genes was calculated per time point, and the mean percentage depletion across the final three time points (264, 312, and 360 h post-transfection), defined in <xref ref-type="fig" rid="F1">fig. 1M</xref> as “average response”, was used for ranking. Ties were resolved by assigning the mean of the tied rank positions.</p></sec><sec id="S14"><title>Cas9 and Cas12a-mediated gene replacement for generation of knockout and tagging cell lines</title><p id="P42">To generate knockout or tagging lines, we used the LeishGEdit approach and previously established primer design strategies targeting the 5′ and 3′ UTRs of each ORF, employing either Cas9 sgRNAs (<xref ref-type="bibr" rid="R132">132</xref>, <xref ref-type="bibr" rid="R138">138</xref>) or Cas12a crRNAs (<xref ref-type="bibr" rid="R58">58</xref>).</p><p id="P43">Donor DNA was generated by PCR-amplifying pTBlast and pTPuro cassettes for knockouts or pPLOT cassettes for tagging, using primers with 25-30 nt homology flanks adjacent to the Cas9 or Cas12a target sites. PCR products were generated and transfected into <italic>L. mexicana</italic> as previously described (<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R132">132</xref>, <xref ref-type="bibr" rid="R138">138</xref>). Cas12a was primarily used, however, Cas9 was employed when Cas12a failed to produce viable mutants. Primer sequences are provided in <xref ref-type="supplementary-material" rid="SD1">supplementary file 8</xref>, along with annotations indicating whether Cas12a or Cas9 was used to achieve successful gene deletion.</p><p id="P44">Successful knockouts and tag insertions were verified by genomic DNA extraction (<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R139">139</xref>) followed by PCR amplification of the targeted loci using ORF-spanning primers (primer design as previously described (<xref ref-type="bibr" rid="R65">65</xref>)), with PF16 (LmxM.20.1400) serving as a positive control. LMT-tagged lines were further validated by Sanger sequencing (<xref ref-type="supplementary-material" rid="SD2">fig. S9</xref>). Most gene deletions were obtained in non-clonal populations using two selectable markers but clonal lines were required to generate complete null mutants for certain targets, including SLS3 (LmxM.34.4990), MFS (LmxM.22.1050), COPE (LmxM.31.1730) and UBC-like (LmxM.21.0440). Due to a limited number of selectable markers, cloning was also necessary for LMT tagging and dependency experiments.</p><p id="P45">Addback constructs were generated by PCR amplification, using two ORF-spanning primers containing SpeI and AflII restriction sites, with 2xMyc tags incorporated either in the forward primer for N-terminal tagging or the reverse primer for C-terminal tagging. The resulting products were ligated into the pTadd plasmid (<xref ref-type="bibr" rid="R65">65</xref>) and transfected as episomes, following established protocols (<xref ref-type="bibr" rid="R132">132</xref>).</p></sec><sec id="S15"><title>Assessing anti-leishmanial drug response in parental and generated mutant cell lines</title><p id="P46">EC<sub>50</sub> values for <italic>L. mexicana</italic> parental and mutant lines (<xref ref-type="supplementary-material" rid="SD1">supplementary file 9</xref>) were determined using a 96-well plate MTT assay previously described (<xref ref-type="bibr" rid="R57">57</xref>), with each strain tested in triplicate across various drug concentrations and being incubated with the respective anti-leishmanial for 48 h. Absorbance values were background-corrected using media controls, normalized to no-drug wells, and fitted to a logistic regression model to calculate the EC<sub>50</sub>. Statistical significance was assessed via one-way ANOVA followed by Dunnett’s post-hoc test.</p><p id="P47">Some mutants exhibited reduced MTT conversion compared to parental cells after incubating 1 x 10<sup>4</sup>, 1 x 10<sup>5</sup>, 1.5 x 10<sup>6</sup> and 3 x 10<sup>6</sup> cells with MTT for 4 hours in drug-free medium (<xref ref-type="supplementary-material" rid="SD2">fig. S11B</xref>). For these lines, and for mutants suspected to exhibit a persister-like drug response phenotype, log-phase promastigotes were diluted to 4 x 10<sup>5</sup> cells/ml in 2 ml and treated with 3.5x EC<sub>50</sub> AmB (105nM) (A9528-50mg Sigma), 2.5x EC<sub>50</sub> MTF (53.75µM) (M5571-50mg Sigma) or 5x EC<sub>50</sub> PTM (3.35µM) (P0547-100mg). Cultures were incubated for 48 hours at 28°C with 5% CO<sub>2</sub> and cell counts were taken at the end of treatment (treatment reads in <xref ref-type="fig" rid="F3">fig. 3D, 3F, 3H</xref>). Cells were then centrifuged, the supernatant discarded, and pellets resuspended in 2 ml of drug-free medium. Parasites were incubated under the same conditions for 48-72 hours (based on recovery rate), and final cell densities were determined (recovery reads in <xref ref-type="fig" rid="F3">fig. 3D, 3F, 3H</xref>).</p></sec><sec id="S16"><title>Imaging of immunofluorescence-labelled and live-cell tagged lines</title><p id="P48">Live-cell imaging of <italic>Leishmania</italic> parasites was performed as previously described (<xref ref-type="bibr" rid="R140">140</xref>). For immunofluorescence staining, ~2 × 10<sup>6</sup> cells were washed and resuspended in PBS. Paraformaldehyde was then added to a final concentration of 1.5%, and cells were fixed for 10 min on ice followed by an additional 30-min incubation at room temperature. Fixed cells were washed in PBS, attached by centrifugation onto poly-L-lysine-coated coverslips, and permeabilized for 5 min with 0.25% Triton X-100 in PBS. Coverslips were washed twice in PBS and blocked in 3% BSA (in PBS) for 30 min at room temperature. Primary antibody incubation was carried out for 1 h at room temperature using anti-Myc mouse monoclonal IgG antibody 4A6 (1:500; 05-724, Sigma-Aldrich) and anti-HA mouse monoclonal IgG antibody 12CA5 (1:500), both diluted in 1% BSA. After three PBS washes, cells were incubated with Alexa Fluor 488 donkey anti-mouse IgG secondary antibody (1:500; A21202, Invitrogen) for 1 hour at room temperature. Following three additional PBS washes, coverslips were mounted onto glass slides using DAPI-Fluoromount G (SouthernBiotech).</p><p id="P49">Both live and stained samples were imaged using a Leica Thunder DMi8 Inverted Widefield Fluorescence Microscope with a ×100 NA 1.30 glycerol immersion objective.</p></sec><sec id="S17"><title>Sterol analysis</title><p id="P50">Mid-log phase promastigotes were washed once with PBS and resuspended in 25% m/v KOH dissolved in 3:2 v/v ethanol:water, followed by heating at 85°C for 1 hour. After cooling, samples were partitioned by vortexing for 30 s with an equal volume of n-heptane (Sigma). After allowing layers to separate for 20 min, the upper organic layer was retained as the sterol extract. For gas chromatography-mass spectrometry (GC-MS, performed at MVLS Shared Research Facilities, Mass Spectrometry), sterol was extracted from 3 x 10<sup>8</sup> parasites in 500 μL n-heptane. Trimethylsilane derivatisation was performed by adding 50 μl MSTFA + 1% TMCS (Thermo Scientific) to 100µL of dried extract, vortexing and incubation at 80°C for 15 min. A retention index was added. GC was performed using 1.0 ml/min Helium carrier gas in a Rxi-5SILMS column (30 m length, 0.25 mm inner diameter, 0.25 μm film thickness, Restek) installed in a Trace Ultra gas chromatograph (Thermo Scientific). Derivatised sample (1 μl) was injected into a split/splitless injector using a surged splitless injection (splitless time 30 s, surge pressure 167 kPa). An initial oven temperature of 70°C was increased to 250°C at a ramp rate of 50°C/min; this was reduced to 10°C/min, with a final temperature of 330°C then held for 3.5 min. Eluting peaks were transferred at an auxiliary transfer temperature of 250°C to an ITQ900-GC mass spectrometer (Thermo Scientific), with an emission current of 250 μA. The ion source was held at 230°C, the full scan mass range was 50–700 m/z with an automatic gain control of 50% and maximum ion time of 50 ms. Blank samples were prepared by heating alcoholic KOH and partitioning with n-heptane. Quality control samples were prepared by pooling equal volumes of all samples. Analysis was performed using Xcalibur Quan Processing 4.7 (Thermo Scientific), with identification either by match to a panel of standards or by comparison to the National Institute of Standards and Technology (NIST) library, also Xcalibur. After calculating initial percentage abundance for different identified peaks, those with a relative abundance of &lt; 0.5% were omitted and percentages recalculated to give the final values shown. For UV spectroscopy, sterol extracts from 8 x 10<sup>7</sup> cells were measured using a Shimadzu UV-2550 UV-Vis spectrophotometer and UVProbe v2.34 software, using n-heptane as a blank. An ergosterol standard spectrum was obtained using 0.05 mg/ml ergosterol (Sigma) in n-heptane. Biological replicates used relate to sterol extracts prepared independently from separate biological samples. A summary of sterol analysis results is provided in <xref ref-type="supplementary-material" rid="SD1">supplementary file 6</xref>.</p></sec><sec id="S18"><title>Lipid analysis</title><p id="P51">Lipids were extracted from cell pellets according to the method described by Folch et al. (<xref ref-type="bibr" rid="R141">141</xref>) by the addition of chloroform/methanol (2/1, v/v). The mixture was left to stand at 4°C for 1 h. The samples were partitioned by the addition of 0.1 M KCl and the mixture was centrifuged to facilitate phase separation. The lower chloroform phase was collected, evaporated to dryness under nitrogen gas and reconstituted in methanol. Global lipidomic analysis was performed by high resolution liquid chromatography-mass spectrometry (LC-MS) using a Waters Select Series Cyclic IMS mass spectrometer (cIMS) equipped with a heated electrospray ionization (Z-spray) probe and interfaced with a Waters Acquity Premier liquid chromatography system. Samples (5 µl) were injected onto a Thermo Hypersil Gold C18 column (1.9 µm; 2.1 mm x 100 mm) maintained at 50°C. Mobile phase A consisted of water containing 10 mM ammonium formate and 0.1% (v/v) formic acid. Mobile phase B consisted of a 90:10 mixture of isopropanol-acetonitrile containing 10 mM ammonium formate and 0.1% (v/v) formic acid. The initial conditions for analysis were 65%A-35%B, increasing to 65%B over 4 min and then to 100%B over 15 min, held for 2 min prior to re-equilibration to the starting conditions over 6 min. The flow rate was 400 µl/min. Samples were analysed in positive and negative ionisation modes over the mass-to-charge ratio (m/z) range of 50 to 2,000 at a resolution of 30,000. Fragmentation was achieved using the MSe function of the cIMS with a ramped collision energy of 25 – 45 kV. Raw LC-MS data was processed with Progenesis QI v2.4 software (Non-linear Dynamics). Relative fold quantification was performed by the software using all ion normalization, followed by data filtering based on the ANOVA score (&lt; 0.05), fold change (&gt; 2) and ANOVA FDR (&lt; 0.05). This was performed for data acquired in both positive and negative ionization modes. Significant features were then identified using both the Lipid Maps and HMDB databases with a mass error tolerance of 5 ppm. A summary of lipid analysis results is provided in <xref ref-type="supplementary-material" rid="SD1">supplementary file 7</xref>.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Files</label><media xlink:href="EMS206974-supplement-Supplementary_Files.zip" mimetype="application" mime-subtype="zip" id="d17aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Figures</label><media xlink:href="EMS206974-supplement-Supplementary_Figures.pdf" mimetype="application" mime-subtype="pdf" id="d17aAcEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S20"><title>Acknowledgement</title><p>We thank all members of the Alsheimer, Engstler, Janzen and Kramer group for helpful discussions and support. In addition, we thank Markus Engstler for providing research resources and infrastructure enabling this project. We thank Joachim Geyer and Isabell Berneburg for providing an aliquot of compound 1c. We thank Eva Gluenz and Andreia Albuquerque-Wendt for helpful discussions regarding Sb<sup>III</sup> resistance in <italic>L. mexicana</italic> and Jessica Valli for discussions on the BBSome in <italic>L. mexicana</italic>. JA and FL were supported by a Flex fund within the LOEWE Center DRUID (Project D3, B3). TB and NHM were supported by the DFG (project 532631727). Additionally, TB was supported by an EMBO Postdoctoral Fellowship (ALTF 727-2021) and Marie Skłodowska-Curie Actions Postdoctoral Fellowship (101064428 – LeishMOM). Lipid and sterol analysis was carried out at the Glasgow University MVLS Shared Research Facility. MPB is funded by the BBSRC (BB/Y007360/1).</p></ack><sec id="S19" sec-type="data-availability"><title>Availability</title><p id="P52">All data generated or analyzed during this study are included in the manuscript and <xref ref-type="supplementary-material" rid="SD1">supplementary files</xref>. CRISPR screening data can be further explored under LeishBASEeditDB, which is an open-source database accessible at <ext-link ext-link-type="uri" xlink:href="https://www.leishbaseeditdb.net">https://www.leishbaseeditdb.net</ext-link>.</p></sec><fn-group><fn fn-type="conflict" id="FN2"><p id="P53"><bold>Declaration of Interests</bold></p><p id="P54">All authors declare that they have no conflicts of interest.</p></fn><fn id="FN3"><p id="P55"><bold>Declaration of Generative AI and AI-Assisted Technologies</bold></p><p id="P56">During the preparation of this work, the author(s) used chatgpt, co-pilot and perplexity for additional literature search and to reduce the number of words in the final manuscript. After using this tool or service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domagalska</surname><given-names>MA</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name></person-group><article-title>Drug resistance in Leishmania: does it really matter?</article-title><source>Trends in parasitology</source><year>2023</year><volume>39</volume><fpage>251</fpage><lpage>259</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="pmid">36803859</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncada-Diaz</surname><given-names>MJ</given-names></name><name><surname>Rodriguez-Almonacid</surname><given-names>CC</given-names></name><name><surname>Quiceno-Giraldo</surname><given-names>E</given-names></name><name><surname>Khuong</surname><given-names>FTH</given-names></name><name><surname>Muskus</surname><given-names>C</given-names></name><name><surname>Karamysheva</surname><given-names>ZN</given-names></name></person-group><article-title>Molecular Mechanisms of Drug Resistance in Leishmania spp</article-title><source>Pathogens</source><year>2024</year><volume>13</volume><comment>published online EpubSep 27</comment><pub-id pub-id-type="doi">10.3390/pathogens13100835</pub-id><pub-id pub-id-type="pmcid">PMC11510721</pub-id><pub-id pub-id-type="pmid">39452707</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponte-Sucre</surname><given-names>A</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Lopez-Velez</surname><given-names>R</given-names></name><name><surname>Garcia-Hernandez</surname><given-names>R</given-names></name><name><surname>Pountain</surname><given-names>AW</given-names></name><name><surname>Mwenechanya</surname><given-names>R</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name></person-group><article-title>Drug resistance and treatment failure in leishmaniasis: A 21st century challenge</article-title><source>PLoS neglected tropical diseases</source><year>2017</year><volume>11</volume><elocation-id>e0006052</elocation-id><comment>published online EpubDec</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0006052</pub-id><pub-id pub-id-type="pmcid">PMC5730103</pub-id><pub-id pub-id-type="pmid">29240765</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salari</surname><given-names>S</given-names></name><name><surname>Bamorovat</surname><given-names>M</given-names></name><name><surname>Sharifi</surname><given-names>I</given-names></name><name><surname>Almani</surname><given-names>PGN</given-names></name></person-group><article-title>Global distribution of treatment resistance gene markers for leishmaniasis</article-title><source>Journal of clinical laboratory analysis</source><year>2022</year><volume>36</volume><elocation-id>e24599</elocation-id><comment>published online EpubAug</comment><pub-id pub-id-type="doi">10.1002/jcla.24599</pub-id><pub-id pub-id-type="pmcid">PMC9396204</pub-id><pub-id pub-id-type="pmid">35808933</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijnant</surname><given-names>GJ</given-names></name><name><surname>Dumetz</surname><given-names>F</given-names></name><name><surname>Dirkx</surname><given-names>L</given-names></name><name><surname>Bulte</surname><given-names>D</given-names></name><name><surname>Cuypers</surname><given-names>B</given-names></name><name><surname>Van Bocxlaer</surname><given-names>K</given-names></name><name><surname>Hendrickx</surname><given-names>S</given-names></name></person-group><article-title>Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis</article-title><source>Front Trop Dis</source><year>2022</year><volume>3</volume><pub-id pub-id-type="doi">10.3389/fitd.2022.837460</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharadava</surname><given-names>K</given-names></name><name><surname>Upadhyay</surname><given-names>TK</given-names></name><name><surname>Kaushal</surname><given-names>RS</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Alraey</surname><given-names>Y</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Saeed</surname><given-names>M</given-names></name></person-group><article-title>Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations</article-title><source>ACS omega</source><year>2024</year><volume>9</volume><fpage>12500</fpage><lpage>12514</lpage><comment>published online EpubMar 19</comment><pub-id pub-id-type="doi">10.1021/acsomega.3c09400</pub-id><pub-id pub-id-type="pmcid">PMC10955595</pub-id><pub-id pub-id-type="pmid">38524425</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>SL</given-names></name><name><surname>Sundar</surname><given-names>S</given-names></name><name><surname>Fairlamb</surname><given-names>AH</given-names></name></person-group><article-title>Drug resistance in leishmaniasis</article-title><source>Clinical microbiology reviews</source><year>2006</year><volume>19</volume><fpage>111</fpage><lpage>126</lpage><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1128/CMR.19.1.111-126.2006</pub-id><pub-id pub-id-type="pmcid">PMC1360270</pub-id><pub-id pub-id-type="pmid">16418526</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hefnawy</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><name><surname>De Muylder</surname><given-names>G</given-names></name></person-group><article-title>Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs</article-title><source>Trends in parasitology</source><year>2017</year><volume>33</volume><fpage>162</fpage><lpage>174</lpage><comment>published online EpubMar</comment><pub-id pub-id-type="pmid">27993477</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Haimeur</surname><given-names>A</given-names></name><name><surname>Grondin</surname><given-names>K</given-names></name><name><surname>Roy</surname><given-names>G</given-names></name><name><surname>Brochu</surname><given-names>C</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name></person-group><article-title>ABC transporters in Leishmania and their role in drug resistance</article-title><source>Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</source><year>1998</year><volume>1</volume><fpage>43</fpage><lpage>48</lpage><comment>published online EpubMar</comment><pub-id pub-id-type="pmid">17092795</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>ABC transporters involved in drug resistance in human parasites</article-title><source>Essays in biochemistry</source><year>2011</year><volume>50</volume><fpage>121</fpage><lpage>144</lpage><comment>published online EpubSep 7</comment><pub-id pub-id-type="pmid">21967055</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Fadili</surname><given-names>K</given-names></name><name><surname>Messier</surname><given-names>N</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Roy</surname><given-names>G</given-names></name><name><surname>Guimond</surname><given-names>C</given-names></name><name><surname>Trudel</surname><given-names>N</given-names></name><name><surname>Saravia</surname><given-names>NG</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes</article-title><source>Antimicrobial agents and chemotherapy</source><year>2005</year><volume>49</volume><fpage>1988</fpage><lpage>1993</lpage><comment>published online EpubMay</comment><pub-id pub-id-type="doi">10.1128/AAC.49.5.1988-1993.2005</pub-id><pub-id pub-id-type="pmcid">PMC1087671</pub-id><pub-id pub-id-type="pmid">15855523</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>JM</given-names></name><name><surname>Parodi-Talice</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>C</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name></person-group><article-title>ABC transporters in the protozoan parasite Leishmania</article-title><source>International microbiology : the official journal of the Spanish Society for Microbiology</source><year>2001</year><volume>4</volume><fpage>159</fpage><lpage>166</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="pmid">11820434</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Santana</surname><given-names>MBR</given-names></name><name><surname>Miranda</surname><given-names>GO</given-names></name><name><surname>Carvalho</surname><given-names>LP</given-names></name></person-group><article-title>ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis</article-title><source>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</source><year>2025</year><volume>151</volume><elocation-id>107315</elocation-id><comment>published online EpubFeb</comment><pub-id pub-id-type="pmid">39613252</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourbal</surname><given-names>B</given-names></name><name><surname>Sonuc</surname><given-names>N</given-names></name><name><surname>Bhattacharjee</surname><given-names>H</given-names></name><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Sundar</surname><given-names>S</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Rosen</surname><given-names>BP</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name></person-group><article-title>Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin</article-title><source>The Journal of biological chemistry</source><year>2004</year><volume>279</volume><fpage>31010</fpage><lpage>31017</lpage><comment>published online EpubJul 23</comment><pub-id pub-id-type="pmid">15138256</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maharjan</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Chatterjee</surname><given-names>M</given-names></name><name><surname>Madhubala</surname><given-names>R</given-names></name></person-group><article-title>Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani</article-title><source>The American journal of tropical medicine and hygiene</source><year>2008</year><volume>79</volume><fpage>69</fpage><lpage>75</lpage><comment>published online EpubJul</comment><pub-id pub-id-type="pmid">18606765</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>G</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Charret</surname><given-names>KS</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name><name><surname>Bhattacharjee</surname><given-names>H</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name></person-group><article-title>Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1</article-title><source>PLoS neglected tropical diseases</source><year>2015</year><volume>9</volume><elocation-id>e0003500</elocation-id><comment>published online EpubFeb</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0003500</pub-id><pub-id pub-id-type="pmcid">PMC4340957</pub-id><pub-id pub-id-type="pmid">25714343</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monte-Neto</surname><given-names>R</given-names></name><name><surname>Laffitte</surname><given-names>MC</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Reis</surname><given-names>P</given-names></name><name><surname>Frezard</surname><given-names>F</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis</article-title><source>PLoS neglected tropical diseases</source><year>2015</year><volume>9</volume><elocation-id>e0003476</elocation-id><comment>published online EpubFeb</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0003476</pub-id><pub-id pub-id-type="pmcid">PMC4332685</pub-id><pub-id pub-id-type="pmid">25679388</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plourde</surname><given-names>M</given-names></name><name><surname>Ubeda</surname><given-names>JM</given-names></name><name><surname>Mandal</surname><given-names>G</given-names></name><name><surname>Monte-Neto</surname><given-names>RL</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Generation of an aquaglyceroporin AQP1 null mutant in Leishmania major</article-title><source>Molecular and biochemical parasitology</source><year>2015</year><volume>201</volume><fpage>108</fpage><lpage>111</lpage><comment>published online EpubJun</comment><pub-id pub-id-type="pmid">26222914</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potvin</surname><given-names>JE</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Queffeulou</surname><given-names>M</given-names></name><name><surname>Sundar</surname><given-names>S</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani</article-title><source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source><year>2021</year><volume>72</volume><fpage>e526</fpage><lpage>e532</lpage><comment>published online EpubMay 18</comment><pub-id pub-id-type="doi">10.1093/cid/ciaa1236</pub-id><pub-id pub-id-type="pmcid">PMC8130028</pub-id><pub-id pub-id-type="pmid">32827255</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunes</surname><given-names>LG</given-names></name><name><surname>Ascher</surname><given-names>DB</given-names></name><name><surname>Pires</surname><given-names>DEV</given-names></name><name><surname>Monte-Neto</surname><given-names>RL</given-names></name></person-group><article-title>The mutation G133D on Leishmania guyanensis AQP1 is highly destabilizing as revealed by molecular modeling and hypo-osmotic shock assay</article-title><source>Biochimica et biophysica acta Biomembranes</source><year>2021</year><volume>1863</volume><elocation-id>183682</elocation-id><comment>published online EpubOct 1</comment><pub-id pub-id-type="pmid">34175297</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquis</surname><given-names>N</given-names></name><name><surname>Gourbal</surname><given-names>B</given-names></name><name><surname>Rosen</surname><given-names>BP</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania</article-title><source>Molecular microbiology</source><year>2005</year><volume>57</volume><fpage>1690</fpage><lpage>1699</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="pmid">16135234</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugani</surname><given-names>JN</given-names></name><name><surname>Gontijo</surname><given-names>CMF</given-names></name><name><surname>Frezard</surname><given-names>F</given-names></name><name><surname>Soares</surname><given-names>RP</given-names></name><name><surname>Monte-Neto</surname><given-names>RLD</given-names></name></person-group><article-title>Antimony resistance in Leishmania (Viannia) braziliensis clinical isolates from atypical lesions associates with increased ARM56/ARM58 transcripts and reduced drug uptake</article-title><source>Memorias do Instituto Oswaldo Cruz</source><year>2019</year><volume>114</volume><elocation-id>e190111</elocation-id><pub-id pub-id-type="doi">10.1590/0074-02760190111</pub-id><pub-id pub-id-type="pmcid">PMC6697410</pub-id><pub-id pub-id-type="pmid">31433006</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>FJ</given-names></name><name><surname>Sanchez-Canete</surname><given-names>MP</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites</article-title><source>The Journal of biological chemistry</source><year>2006</year><volume>281</volume><fpage>23766</fpage><lpage>23775</lpage><comment>published online EpubAug 18</comment><pub-id pub-id-type="pmid">16785229</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>FJ</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug</article-title><source>Antimicrobial agents and chemotherapy</source><year>2003</year><volume>47</volume><fpage>2397</fpage><lpage>2403</lpage><comment>published online EpubAug</comment><pub-id pub-id-type="doi">10.1128/AAC.47.8.2397-2403.2003</pub-id><pub-id pub-id-type="pmcid">PMC166066</pub-id><pub-id pub-id-type="pmid">12878496</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondelaers</surname><given-names>A</given-names></name><name><surname>Sanchez-Canete</surname><given-names>MP</given-names></name><name><surname>Hendrickx</surname><given-names>S</given-names></name><name><surname>Eberhardt</surname><given-names>E</given-names></name><name><surname>Garcia-Hernandez</surname><given-names>R</given-names></name><name><surname>Lachaud</surname><given-names>L</given-names></name><name><surname>Cotton</surname><given-names>J</given-names></name><name><surname>Sanders</surname><given-names>M</given-names></name><name><surname>Cuypers</surname><given-names>B</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes</article-title><source>PloS one</source><year>2016</year><volume>11</volume><elocation-id>e0154101</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154101</pub-id><pub-id pub-id-type="pmcid">PMC4849676</pub-id><pub-id pub-id-type="pmid">27123924</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espada</surname><given-names>CR</given-names></name><name><surname>Albuquerque-Wendt</surname><given-names>A</given-names></name><name><surname>Hornillos</surname><given-names>V</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name><name><surname>Coelho</surname><given-names>AC</given-names></name><name><surname>Uliana</surname><given-names>SRB</given-names></name></person-group><article-title>Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major</article-title><source>ACS infectious diseases</source><year>2021</year><volume>7</volume><fpage>849</fpage><lpage>858</lpage><comment>published online EpubApr 9</comment><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00857</pub-id><pub-id pub-id-type="pmcid">PMC8042657</pub-id><pub-id pub-id-type="pmid">33724800</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>FJ</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name></person-group><article-title>Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance</article-title><source>The Journal of biological chemistry</source><year>2003</year><volume>278</volume><fpage>49965</fpage><lpage>49971</lpage><comment>published online EpubDec 12</comment><pub-id pub-id-type="pmid">14514670</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>R</given-names></name><name><surname>Sen</surname><given-names>SS</given-names></name><name><surname>Muthuswami</surname><given-names>R</given-names></name><name><surname>Madhubala</surname><given-names>R</given-names></name></person-group><article-title>Stigmasterol as a potential biomarker for amphotericin B resistance in Leishmania donovani</article-title><source>The Journal of antimicrobial chemotherapy</source><year>2020</year><volume>75</volume><fpage>942</fpage><lpage>950</lpage><comment>published online EpubApr 1</comment><pub-id pub-id-type="pmid">31886855</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purkait</surname><given-names>B</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Nandi</surname><given-names>N</given-names></name><name><surname>Sardar</surname><given-names>AH</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Pandey</surname><given-names>K</given-names></name><name><surname>Ravidas</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>T</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani</article-title><source>Antimicrobial agents and chemotherapy</source><year>2012</year><volume>56</volume><fpage>1031</fpage><lpage>1041</lpage><comment>published online EpubFeb</comment><pub-id pub-id-type="doi">10.1128/AAC.00030-11</pub-id><pub-id pub-id-type="pmcid">PMC3264217</pub-id><pub-id pub-id-type="pmid">22123699</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwenechanya</surname><given-names>R</given-names></name><name><surname>Kovarova</surname><given-names>J</given-names></name><name><surname>Dickens</surname><given-names>NJ</given-names></name><name><surname>Mudaliar</surname><given-names>M</given-names></name><name><surname>Herzyk</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>IM</given-names></name><name><surname>Weidt</surname><given-names>SK</given-names></name><name><surname>Burgess</surname><given-names>KE</given-names></name><name><surname>Burchmore</surname><given-names>RJS</given-names></name><name><surname>Pountain</surname><given-names>AW</given-names></name><name><surname>Smith</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Sterol 14alpha-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana</article-title><source>PLoS neglected tropical diseases</source><year>2017</year><volume>11</volume><elocation-id>e0005649</elocation-id><comment>published online EpubJun</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0005649</pub-id><pub-id pub-id-type="pmcid">PMC5498063</pub-id><pub-id pub-id-type="pmid">28622334</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pountain</surname><given-names>AW</given-names></name><name><surname>Weidt</surname><given-names>SK</given-names></name><name><surname>Regnault</surname><given-names>C</given-names></name><name><surname>Bates</surname><given-names>PA</given-names></name><name><surname>Donachie</surname><given-names>AM</given-names></name><name><surname>Dickens</surname><given-names>NJ</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name></person-group><article-title>Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites</article-title><source>PLoS neglected tropical diseases</source><year>2019</year><volume>13</volume><elocation-id>e0007052</elocation-id><comment>published online EpubFeb</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0007052</pub-id><pub-id pub-id-type="pmcid">PMC6375703</pub-id><pub-id pub-id-type="pmid">30716073</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelle</surname><given-names>C</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fani</surname><given-names>F</given-names></name><name><surname>Khandelwal</surname><given-names>A</given-names></name><name><surname>Gingras</surname><given-names>H</given-names></name><name><surname>Trottier</surname><given-names>J</given-names></name><name><surname>Barbier</surname><given-names>O</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Burke</surname><given-names>MD</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Well-Tolerated Amphotericin B Derivatives That Effectively Treat Visceral Leishmaniasis</article-title><source>ACS infectious diseases</source><year>2021</year><volume>7</volume><fpage>2472</fpage><lpage>2482</lpage><comment>published online EpubAug 13</comment><pub-id pub-id-type="pmid">34282886</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major</article-title><source>Molecular microbiology</source><year>2019</year><volume>111</volume><fpage>65</fpage><lpage>81</lpage><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1111/mmi.14139</pub-id><pub-id pub-id-type="pmcid">PMC6351164</pub-id><pub-id pub-id-type="pmid">30260041</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakotomanga</surname><given-names>M</given-names></name><name><surname>Blanc</surname><given-names>S</given-names></name><name><surname>Gaudin</surname><given-names>K</given-names></name><name><surname>Chaminade</surname><given-names>P</given-names></name><name><surname>Loiseau</surname><given-names>PM</given-names></name></person-group><article-title>Miltefosine affects lipid metabolism in Leishmania donovani promastigotes</article-title><source>Antimicrobial agents and chemotherapy</source><year>2007</year><volume>51</volume><fpage>1425</fpage><lpage>1430</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1128/AAC.01123-06</pub-id><pub-id pub-id-type="pmcid">PMC1855451</pub-id><pub-id pub-id-type="pmid">17242145</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Queffeulou</surname><given-names>M</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Mejia-Jaramillo</surname><given-names>AM</given-names></name></person-group><article-title>CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum</article-title><source>mBio</source><year>2024</year><volume>15</volume><elocation-id>e0047724</elocation-id><comment>published online EpubJul 17</comment><pub-id pub-id-type="doi">10.1128/mbio.00477-24</pub-id><pub-id pub-id-type="pmcid">PMC11253630</pub-id><pub-id pub-id-type="pmid">38864609</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulloch</surname><given-names>LB</given-names></name><name><surname>Tinti</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>RJ</given-names></name><name><surname>Weidt</surname><given-names>SK</given-names></name><name><surname>Corpas-Lopez</surname><given-names>V</given-names></name><name><surname>Dey</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>TK</given-names></name><name><surname>Fairlamb</surname><given-names>AH</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Wyllie</surname><given-names>S</given-names></name></person-group><article-title>Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1</article-title><source>PLoS pathogens</source><year>2024</year><volume>20</volume><elocation-id>e1012382</elocation-id><comment>published online EpubJul</comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1012382</pub-id><pub-id pub-id-type="pmcid">PMC11265716</pub-id><pub-id pub-id-type="pmid">38991025</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alpizar-Sosa</surname><given-names>EA</given-names></name><name><surname>Ithnin</surname><given-names>NRB</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Pountain</surname><given-names>AW</given-names></name><name><surname>Weidt</surname><given-names>SK</given-names></name><name><surname>Donachie</surname><given-names>AM</given-names></name><name><surname>Ritchie</surname><given-names>R</given-names></name><name><surname>Dickie</surname><given-names>EA</given-names></name><name><surname>Burchmore</surname><given-names>RJS</given-names></name><name><surname>Denny</surname><given-names>PW</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name></person-group><article-title>Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response</article-title><source>PLoS neglected tropical diseases</source><year>2022</year><volume>16</volume><elocation-id>e0010779</elocation-id><comment>published online EpubSep</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0010779</pub-id><pub-id pub-id-type="pmcid">PMC9581426</pub-id><pub-id pub-id-type="pmid">36170238</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazanion</surname><given-names>E</given-names></name><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2016</year><volume>113</volume><fpage>E3012</fpage><lpage>3021</lpage><comment>published online EpubMay 24</comment><pub-id pub-id-type="doi">10.1073/pnas.1520693113</pub-id><pub-id pub-id-type="pmcid">PMC4889358</pub-id><pub-id pub-id-type="pmid">27162331</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Frankfater</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Soares</surname><given-names>RP</given-names></name><name><surname>Cardoso</surname><given-names>CA</given-names></name><name><surname>Nogueira</surname><given-names>PM</given-names></name><name><surname>Lander</surname><given-names>NM</given-names></name><name><surname>Docampo</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>Lathosterol Oxidase (Sterol C-5 Desaturase) Deletion Confers Resistance to Amphotericin B and Sensitivity to Acidic Stress in Leishmania major</article-title><source>mSphere</source><year>2020</year><volume>5</volume><comment>published online EpubJul 1</comment><pub-id pub-id-type="doi">10.1128/mSphere.00380-20</pub-id><pub-id pub-id-type="pmcid">PMC7333571</pub-id><pub-id pub-id-type="pmid">32611698</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>EG</given-names></name><name><surname>Alqaisi</surname><given-names>AQI</given-names></name><name><surname>Godzien</surname><given-names>J</given-names></name><name><surname>Pena</surname><given-names>I</given-names></name><name><surname>Mbekeani</surname><given-names>AJ</given-names></name><name><surname>Alonso-Herranz</surname><given-names>V</given-names></name><name><surname>Lopez-Gonzalvez</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Gabarro</surname><given-names>R</given-names></name><name><surname>Denny</surname><given-names>PW</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine</article-title><source>Antimicrobial agents and chemotherapy</source><year>2018</year><volume>62</volume><comment>published online EpubMay</comment><pub-id pub-id-type="doi">10.1128/AAC.02095-17</pub-id><pub-id pub-id-type="pmcid">PMC5923112</pub-id><pub-id pub-id-type="pmid">29463533</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douanne</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name><name><surname>Bernardo</surname><given-names>L</given-names></name><name><surname>Blanchette</surname><given-names>M</given-names></name><name><surname>Langlais</surname><given-names>D</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name></person-group><article-title>Leishmania parasites exchange drug-resistance genes through extracellular vesicles</article-title><source>Cell reports</source><year>2022</year><volume>40</volume><elocation-id>111121</elocation-id><comment>published online EpubJul 19</comment><pub-id pub-id-type="pmid">35858561</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douanne</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Douanne</surname><given-names>M</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name></person-group><article-title>Unravelling the proteomic signature of extracellular vesicles released by drug-resistant Leishmania infantum parasites</article-title><source>PLoS neglected tropical diseases</source><year>2020</year><volume>14</volume><elocation-id>e0008439</elocation-id><comment>published online EpubJul</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0008439</pub-id><pub-id pub-id-type="pmcid">PMC7365475</pub-id><pub-id pub-id-type="pmid">32628683</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laffitte</surname><given-names>MN</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance</article-title><source>F1000Research</source><year>2016</year><volume>5</volume><elocation-id>2350</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.9218.1</pub-id><pub-id pub-id-type="pmcid">PMC5031125</pub-id><pub-id pub-id-type="pmid">27703673</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zackay</surname><given-names>A</given-names></name><name><surname>Cotton</surname><given-names>JA</given-names></name><name><surname>Sanders</surname><given-names>M</given-names></name><name><surname>Hailu</surname><given-names>A</given-names></name><name><surname>Nasereddin</surname><given-names>A</given-names></name><name><surname>Warburg</surname><given-names>A</given-names></name><name><surname>Jaffe</surname><given-names>CL</given-names></name></person-group><article-title>Genome wide comparison of Ethiopian Leishmania donovani strains reveals differences potentially related to parasite survival</article-title><source>PLoS genetics</source><year>2018</year><volume>14</volume><elocation-id>e1007133</elocation-id><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1371/journal.pgen.1007133</pub-id><pub-id pub-id-type="pmcid">PMC5777657</pub-id><pub-id pub-id-type="pmid">29315303</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Madore</surname><given-names>E</given-names></name><name><surname>Hardiman</surname><given-names>G</given-names></name><name><surname>Corbeil</surname><given-names>J</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum</article-title><source>Nucleic acids research</source><year>2009</year><volume>37</volume><fpage>1387</fpage><lpage>1399</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1093/nar/gkn1069</pub-id><pub-id pub-id-type="pmcid">PMC2655676</pub-id><pub-id pub-id-type="pmid">19129236</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patino</surname><given-names>LH</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Cruz-Saavedra</surname><given-names>L</given-names></name><name><surname>Pavia</surname><given-names>P</given-names></name><name><surname>Muskus</surname><given-names>C</given-names></name><name><surname>Mendez</surname><given-names>C</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><name><surname>Ramirez</surname><given-names>JD</given-names></name></person-group><article-title>Major changes in chromosomal somy, gene expression and gene dosage driven by Sb(III) in Leishmania braziliensis and Leishmania panamensis</article-title><source>Scientific reports</source><year>2019</year><volume>9</volume><elocation-id>9485</elocation-id><comment>published online EpubJul 1</comment><pub-id pub-id-type="doi">10.1038/s41598-019-45538-9</pub-id><pub-id pub-id-type="pmcid">PMC6603004</pub-id><pub-id pub-id-type="pmid">31263131</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamran</surname><given-names>M</given-names></name><name><surname>Bhattacharjee</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>N</given-names></name></person-group><article-title>The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective</article-title><source>Frontiers in cellular and infection microbiology</source><year>2023</year><volume>13</volume><elocation-id>1001973</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1001973</pub-id><pub-id pub-id-type="pmcid">PMC9939536</pub-id><pub-id pub-id-type="pmid">36814446</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickx</surname><given-names>S</given-names></name><name><surname>Reis-Cunha</surname><given-names>JL</given-names></name><name><surname>Forrester</surname><given-names>S</given-names></name><name><surname>Jeffares</surname><given-names>DC</given-names></name><name><surname>Caljon</surname><given-names>G</given-names></name></person-group><article-title>Experimental Selection of Paromomycin Resistance in Leishmania donovani Amastigotes Induces Variable Genomic Polymorphisms</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><comment>published online EpubJul 21</comment><pub-id pub-id-type="doi">10.3390/microorganisms9081546</pub-id><pub-id pub-id-type="pmcid">PMC8398221</pub-id><pub-id pub-id-type="pmid">34442625</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name><name><surname>Gazanion</surname><given-names>E</given-names></name><name><surname>Monte-Neto</surname><given-names>R</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Drug resistance analysis by next generation sequencing in Leishmania</article-title><source>International journal for parasitology</source><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ijpddr.2014.09.005</pub-id><pub-id pub-id-type="pmcid">PMC4412915</pub-id><pub-id pub-id-type="pmid">25941624</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez Guarnizo</surname><given-names>SA</given-names></name><name><surname>Tikhonova</surname><given-names>EB</given-names></name><name><surname>Karamyshev</surname><given-names>AL</given-names></name><name><surname>Muskus</surname><given-names>CE</given-names></name><name><surname>Karamysheva</surname><given-names>ZN</given-names></name></person-group><article-title>Translational reprogramming as a driver of antimony-drug resistance in Leishmania</article-title><source>Nature communications</source><year>2023</year><volume>14</volume><elocation-id>2605</elocation-id><comment>published online EpubMay 5</comment><pub-id pub-id-type="doi">10.1038/s41467-023-38221-1</pub-id><pub-id pub-id-type="pmcid">PMC10163012</pub-id><pub-id pub-id-type="pmid">37147291</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>N</given-names></name><name><surname>Sifri</surname><given-names>CD</given-names></name><name><surname>Henderson</surname><given-names>DM</given-names></name><name><surname>Allen</surname><given-names>T</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Ullman</surname><given-names>B</given-names></name></person-group><article-title>Molecular characterization of the ldmdr1 multidrug resistance gene from Leishmania donovani</article-title><source>Molecular and biochemical parasitology</source><year>1993</year><volume>60</volume><fpage>53</fpage><lpage>64</lpage><comment>published online EpubJul</comment><pub-id pub-id-type="pmid">8103567</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>IM</given-names></name><name><surname>Brotherton</surname><given-names>MC</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Roy</surname><given-names>G</given-names></name><name><surname>Rivas</surname><given-names>L</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>TK</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms</article-title><source>PLoS neglected tropical diseases</source><year>2016</year><volume>10</volume><elocation-id>e0005171</elocation-id><comment>published online EpubDec</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0005171</pub-id><pub-id pub-id-type="pmcid">PMC5135041</pub-id><pub-id pub-id-type="pmid">27911896</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulloch</surname><given-names>LB</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Lima</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>RJ</given-names></name><name><surname>Tinti</surname><given-names>M</given-names></name><name><surname>Pinto</surname><given-names>EG</given-names></name><name><surname>MacLean</surname><given-names>L</given-names></name><name><surname>Wyllie</surname><given-names>S</given-names></name></person-group><article-title>RES-Seq-a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e0180323</elocation-id><comment>published online EpubDec 19</comment><pub-id pub-id-type="doi">10.1128/mbio.01803-23</pub-id><pub-id pub-id-type="pmcid">PMC10746238</pub-id><pub-id pub-id-type="pmid">37929970</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>W</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania</article-title><source>Cell death &amp; disease</source><year>2011</year><volume>2</volume><fpage>e201</fpage><comment>published online EpubSep 1</comment><pub-id pub-id-type="doi">10.1038/cddis.2011.83</pub-id><pub-id pub-id-type="pmcid">PMC3186901</pub-id><pub-id pub-id-type="pmid">21881603</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alpizar-Sosa</surname><given-names>EA</given-names></name><name><surname>Zimbres</surname><given-names>FM</given-names></name><name><surname>Mantilla</surname><given-names>BS</given-names></name><name><surname>Dickie</surname><given-names>EA</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Burle-Caldas</surname><given-names>GA</given-names></name><name><surname>Filipe</surname><given-names>LNS</given-names></name><name><surname>Van Bocxlaer</surname><given-names>K</given-names></name><name><surname>Price</surname><given-names>HP</given-names></name><name><surname>Ibarra-Meneses</surname><given-names>AV</given-names></name><name><surname>Beaudry</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of the Leishmania Inositol Phosphorylceramide Synthase as a Drug Target Using a Chemical and Genetic Approach</article-title><source>ACS infectious diseases</source><year>2024</year><volume>10</volume><fpage>2913</fpage><lpage>2928</lpage><comment>published online EpubAug 9</comment><pub-id pub-id-type="doi">10.1021/acsinfecdis.4c00284</pub-id><pub-id pub-id-type="pmcid">PMC11320567</pub-id><pub-id pub-id-type="pmid">39023360</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Hernandez</surname><given-names>R</given-names></name><name><surname>Manzano</surname><given-names>JI</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>Leishmania donovani develops resistance to drug combinations</article-title><source>PLoS neglected tropical diseases</source><year>2012</year><volume>6</volume><elocation-id>e1974</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001974</pub-id><pub-id pub-id-type="pmcid">PMC3527373</pub-id><pub-id pub-id-type="pmid">23285310</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstler</surname><given-names>M</given-names></name><name><surname>Beneke</surname><given-names>T</given-names></name></person-group><article-title>Gene editing and scalable functional genomic screening in Leishmania species using the CRISPR/Cas9 cytosine base editor toolbox LeishBASEedit</article-title><source>eLife</source><year>2023</year><volume>12</volume><comment>published online EpubMay 24</comment><pub-id pub-id-type="doi">10.7554/eLife.85605</pub-id><pub-id pub-id-type="pmcid">PMC10208639</pub-id><pub-id pub-id-type="pmid">37222701</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann May</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Link</surname><given-names>F</given-names></name><name><surname>Arias-Del-Angel</surname><given-names>J</given-names></name><name><surname>Meiser</surname><given-names>E</given-names></name><name><surname>Beneke</surname><given-names>T</given-names></name></person-group><article-title>Improved base editing and functional screening in Leishmania via co-expression of the AsCas12a ultra variant, a T7 RNA polymerase, and a cytosine base editor</article-title><source>eLife</source><year>2025</year><volume>13</volume><comment>published online EpubFeb 24</comment><pub-id pub-id-type="doi">10.7554/eLife.97437</pub-id><pub-id pub-id-type="pmcid">PMC11850003</pub-id><pub-id pub-id-type="pmid">39991929</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsford</surname><given-names>S</given-names></name><name><surname>Eckert</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Glover</surname><given-names>L</given-names></name><name><surname>Sanchez-Flores</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>KF</given-names></name><name><surname>Turner</surname><given-names>DJ</given-names></name><name><surname>Field</surname><given-names>MC</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name></person-group><article-title>High-throughput decoding of antitrypanosomal drug efficacy and resistance</article-title><source>Nature</source><year>2012</year><volume>482</volume><fpage>232</fpage><lpage>236</lpage><comment>published online EpubJan 25</comment><pub-id pub-id-type="doi">10.1038/nature10771</pub-id><pub-id pub-id-type="pmcid">PMC3303116</pub-id><pub-id pub-id-type="pmid">22278056</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieg</surname><given-names>R</given-names></name><name><surname>Jortzik</surname><given-names>E</given-names></name><name><surname>Goetz</surname><given-names>AA</given-names></name><name><surname>Blandin</surname><given-names>S</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name><name><surname>Elhabiri</surname><given-names>M</given-names></name><name><surname>Rahbari</surname><given-names>M</given-names></name><name><surname>Nuryyeva</surname><given-names>S</given-names></name><name><surname>Voigt</surname><given-names>K</given-names></name><name><surname>Dahse</surname><given-names>HM</given-names></name><name><surname>Brakhage</surname><given-names>A</given-names></name><etal/></person-group><article-title>Arylmethylamino steroids as antiparasitic agents</article-title><source>Nature communications</source><year>2017</year><volume>8</volume><elocation-id>14478</elocation-id><comment>published online EpubFeb 17</comment><pub-id pub-id-type="doi">10.1038/ncomms14478</pub-id><pub-id pub-id-type="pmcid">PMC5321741</pub-id><pub-id pub-id-type="pmid">28211535</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Catta-Preta</surname><given-names>CMC</given-names></name><name><surname>Neish</surname><given-names>R</given-names></name><name><surname>Sadlova</surname><given-names>J</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Alves-Ferreira</surname><given-names>EVC</given-names></name><name><surname>Geoghegan</surname><given-names>V</given-names></name><name><surname>Carnielli</surname><given-names>JBT</given-names></name><name><surname>Newling</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Vojtkova</surname><given-names>B</given-names></name><etal/></person-group><article-title>Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival</article-title><source>Nature communications</source><year>2021</year><volume>12</volume><elocation-id>1244</elocation-id><comment>published online EpubFeb 23</comment><pub-id pub-id-type="doi">10.1038/s41467-021-21360-8</pub-id><pub-id pub-id-type="pmcid">PMC7902614</pub-id><pub-id pub-id-type="pmid">33623024</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhajer</surname><given-names>R</given-names></name><name><surname>Bhattacharyya</surname><given-names>A</given-names></name><name><surname>Didwania</surname><given-names>N</given-names></name><name><surname>Shadab</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>N</given-names></name><name><surname>Palit</surname><given-names>P</given-names></name><name><surname>Vaidya</surname><given-names>T</given-names></name><name><surname>Ali</surname><given-names>N</given-names></name></person-group><article-title>Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis</article-title><source>Biochimica et biophysica acta</source><year>2016</year><volume>1860</volume><fpage>1973</fpage><lpage>1988</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="pmid">27288586</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachidi</surname><given-names>N</given-names></name><name><surname>Taly</surname><given-names>JF</given-names></name><name><surname>Durieu</surname><given-names>E</given-names></name><name><surname>Leclercq</surname><given-names>O</given-names></name><name><surname>Aulner</surname><given-names>N</given-names></name><name><surname>Prina</surname><given-names>E</given-names></name><name><surname>Pescher</surname><given-names>P</given-names></name><name><surname>Notredame</surname><given-names>C</given-names></name><name><surname>Meijer</surname><given-names>L</given-names></name><name><surname>Spath</surname><given-names>GF</given-names></name></person-group><article-title>Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection</article-title><source>Antimicrobial agents and chemotherapy</source><year>2014</year><volume>58</volume><fpage>1501</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1128/AAC.02022-13</pub-id><pub-id pub-id-type="pmcid">PMC3957854</pub-id><pub-id pub-id-type="pmid">24366737</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhiambo</surname><given-names>C</given-names></name><name><surname>Forney</surname><given-names>JD</given-names></name><name><surname>Asai</surname><given-names>DJ</given-names></name><name><surname>LeBowitz</surname><given-names>JH</given-names></name></person-group><article-title>The two cytoplasmic dynein-2 isoforms in Leishmania mexicana perform separate functions</article-title><source>Molecular and biochemical parasitology</source><year>2005</year><volume>143</volume><fpage>216</fpage><lpage>225</lpage><comment>published online EpubOct</comment><pub-id pub-id-type="pmid">16054709</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beneke</surname><given-names>T</given-names></name><name><surname>Demay</surname><given-names>F</given-names></name><name><surname>Hookway</surname><given-names>E</given-names></name><name><surname>Ashman</surname><given-names>N</given-names></name><name><surname>Jeffery</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Valli</surname><given-names>J</given-names></name><name><surname>Becvar</surname><given-names>T</given-names></name><name><surname>Myskova</surname><given-names>J</given-names></name><name><surname>Lestinova</surname><given-names>T</given-names></name><name><surname>Shafiq</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic dissection of a Leishmania flagellar proteome demonstrates requirement for directional motility in sand fly infections</article-title><source>PLoS pathogens</source><year>2019</year><volume>15</volume><elocation-id>e1007828</elocation-id><comment>published online EpubJun 26</comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1007828</pub-id><pub-id pub-id-type="pmcid">PMC6615630</pub-id><pub-id pub-id-type="pmid">31242261</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beneke</surname><given-names>T</given-names></name><name><surname>Neish</surname><given-names>R</given-names></name><name><surname>Catta-Preta</surname><given-names>CMC</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Valli</surname><given-names>J</given-names></name><name><surname>McCoy</surname><given-names>C</given-names></name><name><surname>Albuquerque-Wendt</surname><given-names>A</given-names></name><name><surname>Mottram</surname><given-names>JC</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name></person-group><article-title>IFT and BBSome proteins are required for Leishmania mexicana pathogenicity, but flagellar motility is dispensable</article-title><source>BioRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2024.09.13.612850</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunter</surname><given-names>JD</given-names></name><name><surname>Moreira-Leite</surname><given-names>F</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><article-title>Dependency relationships between IFT-dependent flagellum elongation and cell morphogenesis in Leishmania</article-title><source>Open biology</source><year>2018</year><volume>8</volume><comment>published online EpubNov 21</comment><pub-id pub-id-type="doi">10.1098/rsob.180124</pub-id><pub-id pub-id-type="pmcid">PMC6282073</pub-id><pub-id pub-id-type="pmid">30463910</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero-Martinez</surname><given-names>JM</given-names></name><name><surname>Perez-Pertejo</surname><given-names>Y</given-names></name><name><surname>Reguera</surname><given-names>RM</given-names></name><name><surname>Castro</surname><given-names>MA</given-names></name><name><surname>Rojo</surname><given-names>MV</given-names></name><name><surname>Santiago</surname><given-names>C</given-names></name><name><surname>Abad</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>PA</given-names></name><name><surname>Lopez-Perez</surname><given-names>JL</given-names></name><name><surname>San Feliciano</surname><given-names>A</given-names></name><name><surname>Balana-Fouce</surname><given-names>R</given-names></name></person-group><article-title>Antileishmanial activity and tubulin polymerization inhibition of podophyllotoxin derivatives on Leishmania infantum</article-title><source>International journal for parasitology Drugs and drug resistance</source><year>2017</year><volume>7</volume><fpage>272</fpage><lpage>285</lpage><comment>published online EpubDec</comment><pub-id pub-id-type="doi">10.1016/j.ijpddr.2017.06.003</pub-id><pub-id pub-id-type="pmcid">PMC5512185</pub-id><pub-id pub-id-type="pmid">28719882</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales</surname><given-names>RM</given-names></name><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Crobu</surname><given-names>L</given-names></name><name><surname>Neish</surname><given-names>R</given-names></name><name><surname>Nepal</surname><given-names>B</given-names></name><name><surname>Espeut</surname><given-names>J</given-names></name><name><surname>Pasquier</surname><given-names>G</given-names></name><name><surname>Gillard</surname><given-names>G</given-names></name><name><surname>Cazevieille</surname><given-names>C</given-names></name><name><surname>Mottram</surname><given-names>JC</given-names></name><name><surname>Wetzel</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Tubulin detyrosination shapes Leishmania cytoskeletal architecture and virulence</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2025</year><volume>122</volume><elocation-id>e2415296122</elocation-id><comment>published online EpubJan 21</comment><pub-id pub-id-type="doi">10.1073/pnas.2415296122</pub-id><pub-id pub-id-type="pmcid">PMC11761321</pub-id><pub-id pub-id-type="pmid">39808657</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>AP</given-names></name><name><surname>Vaughan</surname><given-names>S</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><article-title>Evolution of tubulin gene arrays in Trypanosomatid parasites: genomic restructuring in Leishmania</article-title><source>BMC genomics</source><year>2006</year><volume>7</volume><fpage>261</fpage><comment>published online EpubOct 18</comment><pub-id pub-id-type="doi">10.1186/1471-2164-7-261</pub-id><pub-id pub-id-type="pmcid">PMC1621084</pub-id><pub-id pub-id-type="pmid">17044946</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsford</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>DJ</given-names></name><name><surname>Obado</surname><given-names>SO</given-names></name><name><surname>Sanchez-Flores</surname><given-names>A</given-names></name><name><surname>Glover</surname><given-names>L</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Hertz-Fowler</surname><given-names>C</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name></person-group><article-title>High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome</article-title><source>Genome research</source><year>2011</year><volume>21</volume><fpage>915</fpage><lpage>924</lpage><comment>published online EpubJun</comment><pub-id pub-id-type="doi">10.1101/gr.115089.110</pub-id><pub-id pub-id-type="pmcid">PMC3106324</pub-id><pub-id pub-id-type="pmid">21363968</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumetz</surname><given-names>F</given-names></name><name><surname>Cuypers</surname><given-names>B</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Zander</surname><given-names>D</given-names></name><name><surname>D’Haenens</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>I</given-names></name><name><surname>Domagalska</surname><given-names>MA</given-names></name><name><surname>Clos</surname><given-names>J</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><name><surname>De Muylder</surname><given-names>G</given-names></name></person-group><article-title>Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent</article-title><source>mSphere</source><year>2018</year><volume>3</volume><comment>published online EpubApr 25</comment><pub-id pub-id-type="doi">10.1128/mSphere.00548-17</pub-id><pub-id pub-id-type="pmcid">PMC5907651</pub-id><pub-id pub-id-type="pmid">29669889</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachury</surname><given-names>MV</given-names></name><name><surname>Loktev</surname><given-names>AV</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Westlake</surname><given-names>CJ</given-names></name><name><surname>Peranen</surname><given-names>J</given-names></name><name><surname>Merdes</surname><given-names>A</given-names></name><name><surname>Slusarski</surname><given-names>DC</given-names></name><name><surname>Scheller</surname><given-names>RH</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Jackson</surname><given-names>PK</given-names></name></person-group><article-title>A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>1201</fpage><lpage>1213</lpage><comment>published online EpubJun 15</comment><pub-id pub-id-type="pmid">17574030</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinzer</surname><given-names>RA</given-names></name><name><surname>Winter</surname><given-names>AD</given-names></name><name><surname>Page</surname><given-names>AP</given-names></name></person-group><article-title>The relationship between intraflagellar transport and upstream protein trafficking pathways and macrocyclic lactone resistance in Caenorhabditis elegans</article-title><source>G3</source><year>2024</year><volume>14</volume><comment>published online EpubMar 6</comment><pub-id pub-id-type="doi">10.1093/g3journal/jkae009</pub-id><pub-id pub-id-type="pmcid">PMC10917524</pub-id><pub-id pub-id-type="pmid">38227795</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>AP</given-names></name></person-group><article-title>The sensory amphidial structures of Caenorhabditis elegans are involved in macrocyclic lactone uptake and anthelmintic resistance</article-title><source>International journal for parasitology</source><year>2018</year><volume>48</volume><fpage>1035</fpage><lpage>1042</lpage><comment>published online EpubNov</comment><pub-id pub-id-type="doi">10.1016/j.ijpara.2018.06.003</pub-id><pub-id pub-id-type="pmcid">PMC6237615</pub-id><pub-id pub-id-type="pmid">30253131</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>SR</given-names></name><name><surname>Shida</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Aguiar</surname><given-names>M</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Nachury</surname><given-names>MV</given-names></name></person-group><article-title>The conserved Bardet-Biedl syndrome proteins assemble a coat that traffics membrane proteins to cilia</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>1208</fpage><lpage>1219</lpage><comment>published online EpubJun 25</comment><pub-id pub-id-type="doi">10.1016/j.cell.2010.05.015</pub-id><pub-id pub-id-type="pmcid">PMC2898735</pub-id><pub-id pub-id-type="pmid">20603001</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>MC</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name></person-group><article-title>The trypanosome flagellar pocket</article-title><source>Nature reviews Microbiology</source><year>2009</year><volume>7</volume><fpage>775</fpage><lpage>786</lpage><comment>published online EpubNov</comment><pub-id pub-id-type="pmid">19806154</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstler</surname><given-names>M</given-names></name><name><surname>Pfohl</surname><given-names>T</given-names></name><name><surname>Herminghaus</surname><given-names>S</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name><name><surname>Wiegertjes</surname><given-names>G</given-names></name><name><surname>Heddergott</surname><given-names>N</given-names></name><name><surname>Overath</surname><given-names>P</given-names></name></person-group><article-title>Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes</article-title><source>Cell</source><year>2007</year><volume>131</volume><fpage>505</fpage><lpage>515</lpage><comment>published online EpubNov 2</comment><pub-id pub-id-type="pmid">17981118</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>C</given-names></name><name><surname>de Liz</surname><given-names>LV</given-names></name><name><surname>Vaughan</surname><given-names>S</given-names></name><name><surname>Sunter</surname><given-names>JD</given-names></name></person-group><article-title>Disruption of Leishmania flagellum attachment zone architecture causes flagellum loss</article-title><source>Molecular microbiology</source><year>2024</year><volume>121</volume><fpage>53</fpage><lpage>68</lpage><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1111/mmi.15199</pub-id><pub-id pub-id-type="pmcid">PMC10953051</pub-id><pub-id pub-id-type="pmid">38010644</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>I</given-names></name><name><surname>Basak</surname><given-names>R</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name></person-group><article-title>Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by Leishmania</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><comment>published online EpubMay 16</comment><pub-id pub-id-type="doi">10.3390/pathogens11050585</pub-id><pub-id pub-id-type="pmcid">PMC9143042</pub-id><pub-id pub-id-type="pmid">35631106</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koumandou</surname><given-names>VL</given-names></name><name><surname>Klute</surname><given-names>MJ</given-names></name><name><surname>Herman</surname><given-names>EK</given-names></name><name><surname>Nunez-Miguel</surname><given-names>R</given-names></name><name><surname>Dacks</surname><given-names>JB</given-names></name><name><surname>Field</surname><given-names>MC</given-names></name></person-group><article-title>Evolutionary reconstruction of the retromer complex and its function in Trypanosoma brucei</article-title><source>Journal of cell science</source><year>2011</year><volume>124</volume><fpage>1496</fpage><lpage>1509</lpage><comment>published online EpubMay 1</comment><pub-id pub-id-type="doi">10.1242/jcs.081596</pub-id><pub-id pub-id-type="pmcid">PMC3078816</pub-id><pub-id pub-id-type="pmid">21502137</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liew</surname><given-names>GM</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Nager</surname><given-names>AR</given-names></name><name><surname>Murphy</surname><given-names>JP</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Aguiar</surname><given-names>M</given-names></name><name><surname>Breslow</surname><given-names>DK</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Nachury</surname><given-names>V</given-names></name></person-group><article-title>The intraflagellar transport protein IFT27 promotes BBSome exit from cilia through the GTPase ARL6/BBS3</article-title><source>Developmental cell</source><year>2014</year><volume>31</volume><fpage>265</fpage><lpage>278</lpage><comment>published online EpubNov 10</comment><pub-id pub-id-type="doi">10.1016/j.devcel.2014.09.004</pub-id><pub-id pub-id-type="pmcid">PMC4255629</pub-id><pub-id pub-id-type="pmid">25443296</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Valli</surname><given-names>J</given-names></name></person-group><source>The Role of the Leishmania mexicana Amastigote Flagellum in Parasite-Host Interactions</source><publisher-name>PhD thesis, University of Oxford</publisher-name><year>2017</year></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billington</surname><given-names>K</given-names></name><name><surname>Halliday</surname><given-names>C</given-names></name><name><surname>Madden</surname><given-names>R</given-names></name><name><surname>Dyer</surname><given-names>P</given-names></name><name><surname>Barker</surname><given-names>AR</given-names></name><name><surname>Moreira-Leite</surname><given-names>FF</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Vaughan</surname><given-names>S</given-names></name><name><surname>Hertz-Fowler</surname><given-names>C</given-names></name><name><surname>Dean</surname><given-names>S</given-names></name><name><surname>Sunter</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Genome-wide subcellular protein map for the flagellate parasite Trypanosoma brucei</article-title><source>Nature microbiology</source><year>2023</year><volume>8</volume><fpage>533</fpage><lpage>547</lpage><comment>published online EpubMar</comment><pub-id pub-id-type="doi">10.1038/s41564-022-01295-6</pub-id><pub-id pub-id-type="pmcid">PMC9981465</pub-id><pub-id pub-id-type="pmid">36804636</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awata</surname><given-names>J</given-names></name><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Standley</surname><given-names>C</given-names></name><name><surname>Lechtreck</surname><given-names>KF</given-names></name><name><surname>Bellve</surname><given-names>KD</given-names></name><name><surname>Pazour</surname><given-names>GJ</given-names></name><name><surname>Fogarty</surname><given-names>KE</given-names></name><name><surname>Witman</surname><given-names>GB</given-names></name></person-group><article-title>NPHP4 controls ciliary trafficking of membrane proteins and large soluble proteins at the transition zone</article-title><source>Journal of cell science</source><year>2014</year><volume>127</volume><fpage>4714</fpage><lpage>4727</lpage><comment>published online EpubNov 1</comment><pub-id pub-id-type="doi">10.1242/jcs.155275</pub-id><pub-id pub-id-type="pmcid">PMC4215714</pub-id><pub-id pub-id-type="pmid">25150219</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Borgne</surname><given-names>P</given-names></name><name><surname>Greibill</surname><given-names>L</given-names></name><name><surname>Laporte</surname><given-names>MH</given-names></name><name><surname>Lemullois</surname><given-names>M</given-names></name><name><surname>Bouhouche</surname><given-names>K</given-names></name><name><surname>Temagoult</surname><given-names>M</given-names></name><name><surname>Rosnet</surname><given-names>O</given-names></name><name><surname>Le Guennec</surname><given-names>M</given-names></name><name><surname>Lignieres</surname><given-names>L</given-names></name><name><surname>Chevreux</surname><given-names>G</given-names></name><name><surname>Koll</surname><given-names>F</given-names></name><etal/></person-group><article-title>The evolutionary conserved proteins CEP90, FOPNL, and OFD1 recruit centriolar distal appendage proteins to initiate their assembly</article-title><source>PLoS biology</source><year>2022</year><volume>20</volume><elocation-id>e3001782</elocation-id><comment>published online EpubSep</comment><pub-id pub-id-type="doi">10.1371/journal.pbio.3001782</pub-id><pub-id pub-id-type="pmcid">PMC9484695</pub-id><pub-id pub-id-type="pmid">36070319</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burchmore</surname><given-names>RJ</given-names></name><name><surname>Rodriguez-Contreras</surname><given-names>D</given-names></name><name><surname>McBride</surname><given-names>K</given-names></name><name><surname>Merkel</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Modi</surname><given-names>G</given-names></name><name><surname>Sacks</surname><given-names>D</given-names></name><name><surname>Landfear</surname><given-names>SM</given-names></name></person-group><article-title>Genetic characterization of glucose transporter function in Leishmania mexicana</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2003</year><volume>100</volume><fpage>3901</fpage><lpage>3906</lpage><comment>published online EpubApr 1</comment><pub-id pub-id-type="doi">10.1073/pnas.0630165100</pub-id><pub-id pub-id-type="pmcid">PMC153020</pub-id><pub-id pub-id-type="pmid">12651954</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>JL</given-names></name><name><surname>Witman</surname><given-names>GB</given-names></name></person-group><article-title>Intraflagellar transport</article-title><source>Nature reviews Molecular cell biology</source><year>2002</year><volume>3</volume><fpage>813</fpage><lpage>825</lpage><comment>published online EpubNov</comment><pub-id pub-id-type="pmid">12415299</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>FD</given-names></name><name><surname>Sanchez</surname><given-names>MA</given-names></name><name><surname>Landfear</surname><given-names>SM</given-names></name></person-group><article-title>Touching the Surface: Diverse Roles for the Flagellar Membrane in Kinetoplastid Parasites</article-title><source>Microbiology and molecular biology reviews : MMBR</source><year>2020</year><volume>84</volume><comment>published online EpubMay 20</comment><pub-id pub-id-type="doi">10.1128/MMBR.00079-19</pub-id><pub-id pub-id-type="pmcid">PMC7117551</pub-id><pub-id pub-id-type="pmid">32238446</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gluenz</surname><given-names>E</given-names></name><name><surname>Hoog</surname><given-names>JL</given-names></name><name><surname>Smith</surname><given-names>AE</given-names></name><name><surname>Dawe</surname><given-names>HR</given-names></name><name><surname>Shaw</surname><given-names>MK</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><article-title>Beyond 9+0: noncanonical axoneme structures characterize sensory cilia from protists to humans</article-title><source>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</source><year>2010</year><volume>24</volume><fpage>3117</fpage><lpage>3121</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="doi">10.1096/fj.09-151381</pub-id><pub-id pub-id-type="pmcid">PMC2923350</pub-id><pub-id pub-id-type="pmid">20371625</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>JM</given-names></name><name><surname>Goncalves</surname><given-names>LO</given-names></name><name><surname>Liarte</surname><given-names>DB</given-names></name><name><surname>Lima</surname><given-names>DA</given-names></name><name><surname>Guimaraes</surname><given-names>FG</given-names></name><name><surname>Resende de Melo</surname><given-names>D</given-names></name><name><surname>Santi</surname><given-names>AMM</given-names></name><name><surname>de Oliveira</surname><given-names>LM</given-names></name><name><surname>Velloso</surname><given-names>JPL</given-names></name><name><surname>Delfino</surname><given-names>RG</given-names></name><name><surname>Pescher</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines</article-title><source>Parasites &amp; vectors</source><year>2020</year><volume>13</volume><fpage>600</fpage><comment>published online EpubNov 30</comment><pub-id pub-id-type="doi">10.1186/s13071-020-04486-4</pub-id><pub-id pub-id-type="pmcid">PMC7706067</pub-id><pub-id pub-id-type="pmid">33256787</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>S</given-names></name><name><surname>Bharati</surname><given-names>K</given-names></name><name><surname>Shaha</surname><given-names>C</given-names></name><name><surname>Mukhopadhyay</surname><given-names>CK</given-names></name></person-group><article-title>Zinc depletion promotes apoptosis-like death in drug-sensitive and antimony-resistance Leishmania donovani</article-title><source>Scientific reports</source><year>2017</year><volume>7</volume><elocation-id>10488</elocation-id><comment>published online EpubSep 5</comment><pub-id pub-id-type="doi">10.1038/s41598-017-10041-6</pub-id><pub-id pub-id-type="pmcid">PMC5585245</pub-id><pub-id pub-id-type="pmid">28874760</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Mandal</surname><given-names>G</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Bhattacharjee</surname><given-names>H</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name></person-group><article-title>Functional role of lysine 12 in Leishmania major AQP1</article-title><source>Molecular and biochemical parasitology</source><year>2015</year><volume>201</volume><fpage>139</fpage><lpage>145</lpage><comment>published online EpubJun</comment><pub-id pub-id-type="doi">10.1016/j.molbiopara.2015.07.005</pub-id><pub-id pub-id-type="pmcid">PMC4706639</pub-id><pub-id pub-id-type="pmid">26259900</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdmann</surname><given-names>M</given-names></name><name><surname>Scholz</surname><given-names>A</given-names></name><name><surname>Melzer</surname><given-names>IM</given-names></name><name><surname>Schmetz</surname><given-names>C</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name></person-group><article-title>Interacting protein kinases involved in the regulation of flagellar length</article-title><source>Molecular biology of the cell</source><year>2006</year><volume>17</volume><fpage>2035</fpage><lpage>2045</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1091/mbc.E05-10-0976</pub-id><pub-id pub-id-type="pmcid">PMC1415332</pub-id><pub-id pub-id-type="pmid">16467378</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gorcke</surname><given-names>I</given-names></name></person-group><article-title>Identification of mitogen-activated protein kinase homologues from Leishmania mexicana</article-title><source>International journal for parasitology</source><year>2003</year><volume>33</volume><fpage>1577</fpage><lpage>1587</lpage><comment>published online EpubDec</comment><pub-id pub-id-type="pmid">14636673</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>AC</given-names></name><name><surname>Yamashiro-Kanashiro</surname><given-names>EH</given-names></name><name><surname>Bastos</surname><given-names>SF</given-names></name><name><surname>Mortara</surname><given-names>RA</given-names></name><name><surname>Cotrim</surname><given-names>PC</given-names></name></person-group><article-title>Intracellular location of the ABC transporter PRP1 related to pentamidine resistance in Leishmania major</article-title><source>Molecular and biochemical parasitology</source><year>2006</year><volume>150</volume><fpage>378</fpage><lpage>383</lpage><comment>published online EpubDec</comment><pub-id pub-id-type="pmid">17030436</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legare</surname><given-names>D</given-names></name><name><surname>Richard</surname><given-names>D</given-names></name><name><surname>Mukhopadhyay</surname><given-names>R</given-names></name><name><surname>Stierhof</surname><given-names>YD</given-names></name><name><surname>Rosen</surname><given-names>BP</given-names></name><name><surname>Haimeur</surname><given-names>A</given-names></name><name><surname>Papadopoulou</surname><given-names>B</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase</article-title><source>The Journal of biological chemistry</source><year>2001</year><volume>276</volume><fpage>26301</fpage><lpage>26307</lpage><comment>published online EpubJul 13</comment><pub-id pub-id-type="pmid">11306588</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodge</surname><given-names>MA</given-names></name><name><surname>Waller</surname><given-names>RF</given-names></name><name><surname>Chow</surname><given-names>LM</given-names></name><name><surname>Zaman</surname><given-names>MM</given-names></name><name><surname>Cotton</surname><given-names>LM</given-names></name><name><surname>McConville</surname><given-names>MJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><article-title>Localization and activity of multidrug resistance protein 1 in the secretory pathway of Leishmania parasites</article-title><source>Molecular microbiology</source><year>2004</year><volume>51</volume><fpage>1563</fpage><lpage>1575</lpage><comment>published online EpubMar</comment><pub-id pub-id-type="pmid">15009885</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weise</surname><given-names>F</given-names></name><name><surname>Stierhof</surname><given-names>YD</given-names></name><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name><name><surname>Overath</surname><given-names>P</given-names></name></person-group><article-title>Distribution of GPI-anchored proteins in the protozoan parasite Leishmania, based on an improved ultrastructural description using high-pressure frozen cells</article-title><source>Journal of cell science 113 Pt 24</source><year>2000</year><fpage>4587</fpage><lpage>4603</lpage><comment>published online EpubDec</comment><pub-id pub-id-type="pmid">11082051</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Cuypers</surname><given-names>B</given-names></name><name><surname>Bhattarai</surname><given-names>NR</given-names></name><name><surname>Uranw</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Ostyn</surname><given-names>B</given-names></name><name><surname>Dujardin</surname><given-names>JC</given-names></name><name><surname>Rijal</surname><given-names>S</given-names></name><name><surname>Vanaerschot</surname><given-names>M</given-names></name></person-group><article-title>Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain</article-title><source>mBio</source><year>2013</year><volume>4</volume><fpage>e00611</fpage><lpage>00613</lpage><comment>published online EpubOct 8</comment><pub-id pub-id-type="doi">10.1128/mBio.00611-13</pub-id><pub-id pub-id-type="pmcid">PMC3791894</pub-id><pub-id pub-id-type="pmid">24105765</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Phospholipid and sphingolipid metabolism in Leishmania</article-title><source>Molecular and biochemical parasitology</source><year>2010</year><volume>170</volume><fpage>55</fpage><lpage>64</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1016/j.molbiopara.2009.12.004</pub-id><pub-id pub-id-type="pmcid">PMC2815228</pub-id><pub-id pub-id-type="pmid">20026359</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>PW</given-names></name><name><surname>Goulding</surname><given-names>D</given-names></name><name><surname>Ferguson</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>DF</given-names></name></person-group><article-title>Sphingolipid-free Leishmania are defective in membrane trafficking, differentiation and infectivity</article-title><source>Molecular microbiology</source><year>2004</year><volume>52</volume><fpage>313</fpage><lpage>327</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="pmid">15066023</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Showalter</surname><given-names>M</given-names></name><name><surname>Revollo</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Sphingolipids are essential for differentiation but not growth in Leishmania</article-title><source>The EMBO journal</source><year>2003</year><volume>22</volume><fpage>6016</fpage><lpage>6026</lpage><comment>published online EpubNov 17</comment><pub-id pub-id-type="doi">10.1093/emboj/cdg584</pub-id><pub-id pub-id-type="pmcid">PMC275442</pub-id><pub-id pub-id-type="pmid">14609948</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Pompey</surname><given-names>JM</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Key</surname><given-names>P</given-names></name><name><surname>Bandhuvula</surname><given-names>P</given-names></name><name><surname>Saba</surname><given-names>JD</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in Leishmania</article-title><source>The EMBO journal</source><year>2007</year><volume>26</volume><fpage>1094</fpage><lpage>1104</lpage><comment>published online EpubFeb 21</comment><pub-id pub-id-type="doi">10.1038/sj.emboj.7601565</pub-id><pub-id pub-id-type="pmcid">PMC1852826</pub-id><pub-id pub-id-type="pmid">17290222</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Bangs</surname><given-names>JD</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Sphingolipids in parasitic protozoa</article-title><source>Advances in experimental medicine and biology</source><year>2010</year><volume>688</volume><fpage>238</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-6741-1_17</pub-id><pub-id pub-id-type="pmcid">PMC2951629</pub-id><pub-id pub-id-type="pmid">20919659</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>M</given-names></name><name><surname>Turnbull</surname><given-names>T</given-names></name><name><surname>Sebastian</surname><given-names>S</given-names></name><name><surname>Kempson</surname><given-names>I</given-names></name></person-group><article-title>The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis</article-title><source>International journal of molecular sciences</source><year>2021</year><volume>22</volume><comment>published online EpubNov 26</comment><pub-id pub-id-type="doi">10.3390/ijms222312827</pub-id><pub-id pub-id-type="pmcid">PMC8657538</pub-id><pub-id pub-id-type="pmid">34884632</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basselin</surname><given-names>M</given-names></name><name><surname>Denise</surname><given-names>H</given-names></name><name><surname>Coombs</surname><given-names>GH</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name></person-group><article-title>Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion</article-title><source>Antimicrobial agents and chemotherapy</source><year>2002</year><volume>46</volume><fpage>3731</fpage><lpage>3738</lpage><comment>published online EpubDec</comment><pub-id pub-id-type="doi">10.1128/AAC.46.12.3731-3738.2002</pub-id><pub-id pub-id-type="pmcid">PMC132791</pub-id><pub-id pub-id-type="pmid">12435669</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Padmanabhan</surname><given-names>PK</given-names></name><name><surname>Sahani</surname><given-names>MH</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Madhubala</surname><given-names>R</given-names></name></person-group><article-title>Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani</article-title><source>Molecular and biochemical parasitology</source><year>2006</year><volume>145</volume><fpage>1</fpage><lpage>10</lpage><comment>published online EpubJan</comment><pub-id pub-id-type="pmid">16219371</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haram</surname><given-names>CS</given-names></name><name><surname>Moitra</surname><given-names>S</given-names></name><name><surname>Keane</surname><given-names>R</given-names></name><name><surname>Kuhlmann</surname><given-names>FM</given-names></name><name><surname>Frankfater</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Keyel</surname><given-names>PA</given-names></name></person-group><article-title>The sphingolipids ceramide and inositol phosphorylceramide protect the Leishmania major membrane from sterol-specific toxins</article-title><source>The Journal of biological chemistry</source><year>2023</year><volume>299</volume><elocation-id>104745</elocation-id><comment>published online EpubJun</comment><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104745</pub-id><pub-id pub-id-type="pmcid">PMC10209034</pub-id><pub-id pub-id-type="pmid">37094699</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Moitra</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Hernandez</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>Sterol 14-alpha-demethylase is vital for mitochondrial functions and stress tolerance in Leishmania major</article-title><source>PLoS pathogens</source><year>2020</year><volume>16</volume><elocation-id>e1008810</elocation-id><comment>published online EpubAug</comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1008810</pub-id><pub-id pub-id-type="pmcid">PMC7462297</pub-id><pub-id pub-id-type="pmid">32817704</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanys-Munoz</surname><given-names>E</given-names></name><name><surname>Perez-Victoria</surname><given-names>JM</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name></person-group><article-title>Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement</article-title><source>Antimicrobial agents and chemotherapy</source><year>2008</year><volume>52</volume><fpage>3573</fpage><lpage>3579</lpage><comment>published online EpubOct</comment><pub-id pub-id-type="doi">10.1128/AAC.00587-08</pub-id><pub-id pub-id-type="pmcid">PMC2565886</pub-id><pub-id pub-id-type="pmid">18644961</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Khoury</surname><given-names>C</given-names></name><name><surname>Thoumi</surname><given-names>S</given-names></name><name><surname>Tokajian</surname><given-names>S</given-names></name><name><surname>Sinno</surname><given-names>A</given-names></name><name><surname>Nemer</surname><given-names>G</given-names></name><name><surname>El Beyrouthy</surname><given-names>M</given-names></name><name><surname>Rahy</surname><given-names>K</given-names></name></person-group><article-title>ABC transporter inhibition by beauvericin partially overcomes drug resistance in Leishmania tropica</article-title><source>Antimicrobial agents and chemotherapy</source><year>2024</year><volume>68</volume><elocation-id>e0136823</elocation-id><comment>published online EpubMay 2</comment><pub-id pub-id-type="doi">10.1128/aac.01368-23</pub-id><pub-id pub-id-type="pmcid">PMC11064568</pub-id><pub-id pub-id-type="pmid">38572959</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perea</surname><given-names>A</given-names></name><name><surname>Manzano</surname><given-names>JI</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance</article-title><source>Antimicrobial agents and chemotherapy</source><year>2016</year><volume>60</volume><fpage>3489</fpage><lpage>3496</lpage><comment>published online EpubJun</comment><pub-id pub-id-type="doi">10.1128/AAC.02813-15</pub-id><pub-id pub-id-type="pmcid">PMC4879363</pub-id><pub-id pub-id-type="pmid">27021316</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>AC</given-names></name><name><surname>Messier</surname><given-names>N</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Cotrim</surname><given-names>PC</given-names></name></person-group><article-title>Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes</article-title><source>Antimicrobial agents and chemotherapy</source><year>2007</year><volume>51</volume><fpage>3030</fpage><lpage>3032</lpage><comment>published online EpubAug</comment><pub-id pub-id-type="doi">10.1128/AAC.00404-07</pub-id><pub-id pub-id-type="pmcid">PMC1932501</pub-id><pub-id pub-id-type="pmid">17452480</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>JM</given-names></name><name><surname>Di Pietro</surname><given-names>A</given-names></name><name><surname>Barron</surname><given-names>D</given-names></name><name><surname>Ravelo</surname><given-names>AG</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents</article-title><source>Current drug targets</source><year>2002</year><volume>3</volume><fpage>311</fpage><lpage>333</lpage><comment>published online EpubAug</comment><pub-id pub-id-type="pmid">12102602</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullman</surname><given-names>B</given-names></name></person-group><article-title>Multidrug resistance and P-glycoproteins in parasitic protozoa</article-title><source>Journal of bioenergetics and biomembranes</source><year>1995</year><volume>27</volume><fpage>77</fpage><lpage>84</lpage><comment>published online EpubFeb</comment><pub-id pub-id-type="pmid">7629055</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouellette</surname><given-names>M</given-names></name><name><surname>Fase-Fowler</surname><given-names>F</given-names></name><name><surname>Borst</surname><given-names>P</given-names></name></person-group><article-title>The amplified H circle of methotrexate-resistant leishmania tarentolae contains a novel P-glycoprotein gene</article-title><source>The EMBO journal</source><year>1990</year><volume>9</volume><fpage>1027</fpage><lpage>1033</lpage><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb08206.x</pub-id><pub-id pub-id-type="pmcid">PMC551774</pub-id><pub-id pub-id-type="pmid">1969794</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>A</given-names></name><name><surname>Siddiqui</surname><given-names>NA</given-names></name><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Murti</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>K</given-names></name><name><surname>Padmakar</surname><given-names>S</given-names></name><name><surname>Pal</surname><given-names>B</given-names></name></person-group><article-title>Combination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence</article-title><source>Indian journal of dermatology</source><year>2024</year><volume>69</volume><fpage>396</fpage><lpage>405</lpage><comment>published online EpubSep-Oct</comment><pub-id pub-id-type="doi">10.4103/ijd.ijd_612_22</pub-id><pub-id pub-id-type="pmcid">PMC11623426</pub-id><pub-id pub-id-type="pmid">39649981</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickx</surname><given-names>S</given-names></name><name><surname>Beyers</surname><given-names>J</given-names></name><name><surname>Mondelaers</surname><given-names>A</given-names></name><name><surname>Eberhardt</surname><given-names>E</given-names></name><name><surname>Lachaud</surname><given-names>L</given-names></name><name><surname>Delputte</surname><given-names>P</given-names></name><name><surname>Cos</surname><given-names>P</given-names></name><name><surname>Maes</surname><given-names>L</given-names></name></person-group><article-title>Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum</article-title><source>The Journal of antimicrobial chemotherapy</source><year>2016</year><volume>71</volume><fpage>1914</fpage><lpage>1921</lpage><comment>published online EpubJul</comment><pub-id pub-id-type="pmid">27084919</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Hernandez</surname><given-names>R</given-names></name><name><surname>Gomez-Perez</surname><given-names>V</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name></person-group><article-title>Fitness of Leishmania donovani parasites resistant to drug combinations</article-title><source>PLoS neglected tropical diseases</source><year>2015</year><volume>9</volume><elocation-id>e0003704</elocation-id><comment>published online EpubApr</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0003704</pub-id><pub-id pub-id-type="pmcid">PMC4388546</pub-id><pub-id pub-id-type="pmid">25849149</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Kyle</surname><given-names>DE</given-names></name><name><surname>Sibley</surname><given-names>LD</given-names></name><name><surname>Radke</surname><given-names>JB</given-names></name><name><surname>Tarleton</surname><given-names>RL</given-names></name></person-group><article-title>Protozoan persister-like cells and drug treatment failure</article-title><source>Nature reviews Microbiology</source><year>2019</year><volume>17</volume><fpage>607</fpage><lpage>620</lpage><comment>published online EpubOct</comment><pub-id pub-id-type="doi">10.1038/s41579-019-0238-x</pub-id><pub-id pub-id-type="pmcid">PMC7024564</pub-id><pub-id pub-id-type="pmid">31444481</pub-id></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albuquerque-Wendt</surname><given-names>A</given-names></name><name><surname>McCoy</surname><given-names>C</given-names></name><name><surname>Neish</surname><given-names>R</given-names></name><name><surname>Dobramysl</surname><given-names>U</given-names></name><name><surname>Alagoz</surname><given-names>C</given-names></name><name><surname>Beneke</surname><given-names>T</given-names></name><name><surname>Cowley</surname><given-names>SA</given-names></name><name><surname>Crouch</surname><given-names>K</given-names></name><name><surname>Wheeler</surname><given-names>RJ</given-names></name><name><surname>Mottram</surname><given-names>JC</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name></person-group><article-title>TransLeish: Identification of membrane transporters essential for survival of intracellular Leishmania parasites in a systematic gene deletion screen</article-title><source>Nature communications</source><year>2025</year><volume>16</volume><fpage>299</fpage><comment>published online EpubJan 2</comment><pub-id pub-id-type="doi">10.1038/s41467-024-55538-7</pub-id><pub-id pub-id-type="pmcid">PMC11696137</pub-id><pub-id pub-id-type="pmid">39747086</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>G</given-names></name><name><surname>Fuchs</surname><given-names>M</given-names></name><name><surname>McConville</surname><given-names>MJ</given-names></name><name><surname>Stierhof</surname><given-names>YD</given-names></name><name><surname>Overath</surname><given-names>P</given-names></name></person-group><article-title>Surface antigens of Leishmania mexicana amastigotes: characterization of glycoinositol phospholipids and a macrophage-derived glycosphingolipid</article-title><source>Journal of cell science</source><year>1994</year><volume>107</volume><issue>Pt 9</issue><fpage>2471</fpage><lpage>2482</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="pmid">7844164</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>HZ</given-names></name><name><surname>Harding</surname><given-names>CR</given-names></name><name><surname>Denny</surname><given-names>PW</given-names></name></person-group><article-title>Endocytosis and Sphingolipid Scavenging in Leishmania mexicana Amastigotes</article-title><source>Biochemistry research international</source><year>2012</year><volume>2012</volume><elocation-id>691363</elocation-id><pub-id pub-id-type="doi">10.1155/2012/691363</pub-id><pub-id pub-id-type="pmcid">PMC3177366</pub-id><pub-id pub-id-type="pmid">21941657</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Docampo</surname><given-names>R</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Leishmania salvage and remodelling of host sphingolipids in amastigote survival and acidocalcisome biogenesis</article-title><source>Molecular microbiology</source><year>2005</year><volume>55</volume><fpage>1566</fpage><lpage>1578</lpage><comment>published online EpubMar</comment><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04493.x</pub-id><pub-id pub-id-type="pmcid">PMC3803142</pub-id><pub-id pub-id-type="pmid">15720561</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhlmann</surname><given-names>FM</given-names></name><name><surname>Key</surname><given-names>PN</given-names></name><name><surname>Hickerson</surname><given-names>SM</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Beverley</surname><given-names>SM</given-names></name></person-group><article-title>Inositol phosphorylceramide synthase null Leishmania are viable and virulent in animal infections where salvage of host sphingomyelin predominates</article-title><source>The Journal of biological chemistry</source><year>2022</year><volume>298</volume><elocation-id>102522</elocation-id><comment>published online EpubNov</comment><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102522</pub-id><pub-id pub-id-type="pmcid">PMC9637897</pub-id><pub-id pub-id-type="pmid">36162499</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>K</given-names></name><name><surname>Perez-Victoria</surname><given-names>FJ</given-names></name><name><surname>Stettler</surname><given-names>M</given-names></name><name><surname>Sanchez-Canete</surname><given-names>MP</given-names></name><name><surname>Castanys</surname><given-names>S</given-names></name><name><surname>Gamarro</surname><given-names>F</given-names></name><name><surname>Croft</surname><given-names>SL</given-names></name></person-group><article-title>Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo</article-title><source>International journal of antimicrobial agents</source><year>2007</year><volume>30</volume><fpage>229</fpage><lpage>235</lpage><comment>published online EpubSep</comment><pub-id pub-id-type="pmid">17628445</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>HP</given-names></name><name><surname>Paape</surname><given-names>D</given-names></name><name><surname>Hodgkinson</surname><given-names>MR</given-names></name><name><surname>Farrant</surname><given-names>K</given-names></name><name><surname>Doehl</surname><given-names>J</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>DF</given-names></name></person-group><article-title>The Leishmania major BBSome subunit BBS1 is essential for parasite virulence in the mammalian host</article-title><source>Molecular microbiology</source><year>2013</year><volume>90</volume><fpage>597</fpage><lpage>611</lpage><comment>published online EpubNov</comment><pub-id pub-id-type="doi">10.1111/mmi.12383</pub-id><pub-id pub-id-type="pmcid">PMC3916885</pub-id><pub-id pub-id-type="pmid">23998526</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zauli</surname><given-names>RC</given-names></name><name><surname>Yokoyama-Yasunaka</surname><given-names>JK</given-names></name><name><surname>Miguel</surname><given-names>DC</given-names></name><name><surname>Moura</surname><given-names>AS</given-names></name><name><surname>Pereira</surname><given-names>L</given-names></name><name><surname>da Silva</surname><given-names>IA</given-names></name><name><surname>Lemes</surname><given-names>LG</given-names></name><name><surname>Dorta</surname><given-names>ML</given-names></name><name><surname>de Oliveira</surname><given-names>MA</given-names></name><name><surname>Pitaluga</surname><given-names>AN</given-names></name><name><surname>Ishikawa</surname><given-names>EA</given-names></name><etal/></person-group><article-title>A dysflagellar mutant of Leishmania (Viannia) braziliensis isolated from a cutaneous leishmaniasis patient</article-title><source>Parasites &amp; vectors</source><year>2012</year><volume>5</volume><fpage>11</fpage><comment>published online EpubJan 11</comment><pub-id pub-id-type="doi">10.1186/1756-3305-5-11</pub-id><pub-id pub-id-type="pmcid">PMC3271977</pub-id><pub-id pub-id-type="pmid">22236464</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Prada</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Plourde</surname><given-names>M</given-names></name><name><surname>Bresson</surname><given-names>E</given-names></name><name><surname>Roy</surname><given-names>G</given-names></name><name><surname>Leprohon</surname><given-names>P</given-names></name><name><surname>Ouellette</surname><given-names>M</given-names></name></person-group><article-title>High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms</article-title><source>International journal for parasitology Drugs and drug resistance</source><year>2018</year><volume>8</volume><fpage>165</fpage><lpage>173</lpage><comment>published online EpubMar 16</comment><pub-id pub-id-type="doi">10.1016/j.ijpddr.2018.03.004</pub-id><pub-id pub-id-type="pmcid">PMC6039308</pub-id><pub-id pub-id-type="pmid">29602064</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>Barkal</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Jankowiak</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Francoeur</surname><given-names>M</given-names></name><name><surname>Phan</surname><given-names>QV</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Tognon</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification</article-title><source>Nature genetics</source><year>2024</year><volume>56</volume><fpage>925</fpage><lpage>937</lpage><comment>published online EpubMay</comment><pub-id pub-id-type="doi">10.1038/s41588-024-01726-6</pub-id><pub-id pub-id-type="pmcid">PMC11669423</pub-id><pub-id pub-id-type="pmid">38658794</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beneke</surname><given-names>T</given-names></name><name><surname>Madden</surname><given-names>R</given-names></name><name><surname>Makin</surname><given-names>L</given-names></name><name><surname>Valli</surname><given-names>J</given-names></name><name><surname>Sunter</surname><given-names>J</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name></person-group><article-title>A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids</article-title><source>Royal Society open science</source><year>2017</year><volume>4</volume><elocation-id>170095</elocation-id><comment>published online EpubMay</comment><pub-id pub-id-type="doi">10.1098/rsos.170095</pub-id><pub-id pub-id-type="pmcid">PMC5451818</pub-id><pub-id pub-id-type="pmid">28573017</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslett</surname><given-names>M</given-names></name><name><surname>Aurrecoechea</surname><given-names>C</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Brestelli</surname><given-names>J</given-names></name><name><surname>Brunk</surname><given-names>BP</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Depledge</surname><given-names>DP</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Gajria</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Gardner</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>TriTrypDB: a functional genomic resource for the Trypanosomatidae</article-title><source>Nucleic acids research</source><year>2010</year><volume>38</volume><fpage>D457</fpage><lpage>462</lpage><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1093/nar/gkp851</pub-id><pub-id pub-id-type="pmcid">PMC2808979</pub-id><pub-id pub-id-type="pmid">19843604</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugasundram</surname><given-names>A</given-names></name><name><surname>Starns</surname><given-names>D</given-names></name><name><surname>Bohme</surname><given-names>U</given-names></name><name><surname>Amos</surname><given-names>B</given-names></name><name><surname>Wilkinson</surname><given-names>PA</given-names></name><name><surname>Harb</surname><given-names>OS</given-names></name><name><surname>Warrenfeltz</surname><given-names>S</given-names></name><name><surname>Kissinger</surname><given-names>JC</given-names></name><name><surname>McDowell</surname><given-names>MA</given-names></name><name><surname>Roos</surname><given-names>DS</given-names></name><name><surname>Crouch</surname><given-names>K</given-names></name><etal/></person-group><article-title>TriTrypDB: An integrated functional genomics resource for kinetoplastida</article-title><source>PLoS neglected tropical diseases</source><year>2023</year><volume>17</volume><elocation-id>e0011058</elocation-id><comment>published online EpubJan</comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0011058</pub-id><pub-id pub-id-type="pmcid">PMC9888696</pub-id><pub-id pub-id-type="pmid">36656904</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Fusi</surname><given-names>N</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Wilen</surname><given-names>C</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature biotechnology</source><year>2016</year><volume>34</volume><fpage>184</fpage><lpage>191</lpage><comment>published online EpubFeb</comment><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmcid">PMC4744125</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><article-title>Cutadapt Removes Adapter Sequences From High-Throughput Sequencing Reads</article-title><source>EMBnetjournal Bioinformatic in Action</source><volume>17</volume><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome biology</source><year>2014</year><volume>15</volume><fpage>554</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmcid">PMC4290824</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beneke</surname><given-names>T</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name></person-group><article-title>LeishGEdit: A Method for Rapid Gene Knockout and Tagging Using CRISPR-Cas9</article-title><source>Methods in molecular biology</source><year>2019</year><volume>1971</volume><fpage>189</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">30980304</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotureau</surname><given-names>B</given-names></name><name><surname>Gego</surname><given-names>A</given-names></name><name><surname>Carme</surname><given-names>B</given-names></name></person-group><article-title>Trypanosomatid protozoa: a simplified DNA isolation procedure</article-title><source>Experimental parasitology</source><year>2005</year><volume>111</volume><fpage>207</fpage><lpage>209</lpage><comment>published online EpubNov</comment><pub-id pub-id-type="pmid">16139269</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>RJ</given-names></name><name><surname>Gluenz</surname><given-names>E</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><article-title>Basal body multipotency and axonemal remodelling are two pathways to a 9+0 flagellum</article-title><source>Nature communications</source><year>2015</year><volume>6</volume><elocation-id>8964</elocation-id><comment>published online EpubDec 15</comment><pub-id pub-id-type="doi">10.1038/ncomms9964</pub-id><pub-id pub-id-type="pmcid">PMC4682162</pub-id><pub-id pub-id-type="pmid">26667778</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Sloane Stanley</surname><given-names>GH</given-names></name></person-group><article-title>A simple method for the isolation and purification of total lipides from animal tissues</article-title><source>The Journal of biological chemistry</source><year>1957</year><volume>226</volume><fpage>497</fpage><lpage>509</lpage><comment>published online EpubMay</comment><pub-id pub-id-type="pmid">13428781</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Base editing enables genome-wide loss-of-function screening in <italic>L. mexicana</italic>.</title><p><bold>(A)</bold> Schematic representation of Cas12a-mediated integration of the CBE sgRNA expression library, as described previously (<xref ref-type="bibr" rid="R58">58</xref>).</p><p><bold>(B)</bold> Workflow of the genome-wide loss-of-function screen performed in <italic>L. mexicana</italic> across three independent biological replicates. “+TR” and “−TR” indicate time points with and without drug treatment, respectively, for each anti-leishmanial screen.</p><p><bold>(C-K)</bold> Median values of sgRNA sets targeting 7,718 unique or multi-gene targets are shown. Error bars represent standard deviations from three biological replicates. The number of significantly enriched or depleted sgRNA sets is indicated for each panel, using thresholds of ≤−1 or ≥1 for log<sub>2</sub> fold change and ≤−4.3219 for log<sub>2</sub> p-value. Comparisons shown include: <bold>(C)</bold> plasmid reference (0 h) vs. post-transfection time points (96 h, 144 h, 192 h, 264 h, 312 h, 360 h), and <bold>(D-K)</bold> plasmid reference (0 h) vs. 360 h read. Highlighted sets include: <bold>(C)</bold> all targets, non-targets, depleted targets, and enriched targets, <bold>(G)</bold> multi-gene targets, <bold>(J)</bold> unclassified genes lacking GO annotations, as well as <bold>(D-K)</bold> selected GO terms and representative genes (highlighted as circles), including <bold>(D)</bold> intraciliary transport particle (GO:0030990),</p><p><bold>(E)</bold> protein kinase activity (GO:0004672), <bold>(F)</bold> ribosome (GO:0005840), <bold>(H)</bold> biosynthetic process (GO:0009058), <bold>(I)</bold> mitochondrion (GO:0005739) and <bold>(K)</bold> transmembrane transporter activity (GO:0022857).</p><p><bold>(L)</bold> Doubling times of generated null mutants. Error bars represent standard deviation across triplicates.</p><p><bold>(M)</bold> GO Term rank analysis: The average percentage of depleted genes per GO term class (with a minimum of 10 genes/class) is plotted against its average rank across replicates.</p><p><bold>(N)</bold> Comparison of the 144 h post-transfection sample vs. the upper transwell fraction. Left panel: Log<sub>2</sub> p-value and log<sub>2</sub> fold change of median sgRNA sets; right panel: individual sgRNA values. Highlighted are non-targeting controls and sgRNA sets associated with the GO term “Intraciliary transport particles” (GO:0030990), with the number of significantly enriched or depleted sgRNA sets and individual sgRNAs indicated (using thresholds of ≤−1 or ≥1 for log<sub>2</sub> fold change and ≤−4.3219 for log<sub>2</sub> p-value).</p></caption><graphic xlink:href="EMS206974-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Genome-wide screen identifies <italic>L. mexicana</italic> drug resistance and sensitivity markers.</title><p><bold>(A-E)</bold> Median values of sgRNA sets targeting 7,718 unique or multi-gene targets are shown. Error bars represent standard deviations from three biological replicates. The comparison shown is between recovery fractions and their corresponding viability screen time points (192 h vs. recovery 1, 264 h vs. recovery 2). Legends below each plot highlight selected genes discussed in the text. The number of significantly enriched or depleted non-targeting (yellow) and targeting (grey) sgRNA sets are indicated in the far left panel of each figure element, using thresholds of ≤−1 or ≥1 for log2 fold change and ≤−4.3219 for log2 p-value.</p><p><bold>Footnotes:</bold> <sup><bold><underline>1</underline></bold></sup> Sb<sup>III &amp;</sup> 1c enriched; <sup><bold><underline>2</underline></bold></sup> Sb<sup>III &amp;</sup> PTM enriched; <sup><bold><underline>3</underline></bold></sup> Sb<sup>III</sup> depleted &amp; MTF enriched; <sup><bold><underline>4</underline></bold></sup> Sb<sup>III &amp;</sup> AmB depleted &amp; MTF enriched; <sup><bold><underline>5</underline></bold></sup> AmB &amp; MTF enriched; <sup><bold><underline>6</underline></bold></sup> AmB enriched &amp; PTM depleted; <sup><bold><underline>7</underline></bold></sup> AmB depleted &amp; PTM enriched; <sup><bold><underline>8</underline></bold></sup> Paralogous genes with opposing drug response.</p><p><bold>(F, G)</bold> Simplified KEGG pathway diagrams for <bold>(F)</bold> steroid metabolism and <bold>(G)</bold> sphingolipid metabolism. Genes from these pathways included in the screen are labelled with their EC numbers and highlighted in grey; matching colours are used for corresponding gene markers in panels <bold>(C)</bold> and <bold>(E)</bold>. Key metabolic products are highlighted in red.</p></caption><graphic xlink:href="EMS206974-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Individual mutant verification confirms data from genome-wide screen.</title><p><bold>(A, B, C, E, G)</bold> EC<sub>50</sub> values are shown for each tested cell line following an MTT assay, including parental controls, knockouts, and addbacks as indicated. Each filled-colored dot represents the mean EC<sub>50</sub> from up to nine biological replicates (individual replicates shown as grey unfilled dots), with error bars representing the 95% confidence interval (CI). The 95% CI for the parental Cas12a-expressing strain (PARCas12a) is indicated as a grey dotted line for reference.</p><p><bold>(D, F, H)</bold> Parasite cell lines were treated with drug for 48 h and then allowed to recover in drug-free medium for 48–72 h. Cell densities were measured at the end of the treatment phase and after the recovery phase, and plotted accordingly.</p><p>For all panels, statistical comparisons between mutant strains and the PARCas12a strain were performed using a one-way ANOVA followed by Dunnett’s post-hoc test (significance threshold: p = 0.05; significant differences marked with an asterisk). Additionally, EC<sub>50</sub> values for individual addback strains were compared to their corresponding knockout strains using a two-tailed t-test (p = 0.05; significant differences marked with a dagger †).</p></caption><graphic xlink:href="EMS206974-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Drug response markers reveal cross-resistance and collateral sensitivities.</title><p>Circos plot displays genome-wide enrichment and depletion of all 7,718 unique or multi-gene sgRNA target sets, mapped to their chromosomal positions. Values represent scaled log<sub>2</sub> p-values for the median of each sgRNA set, averaged across three biological replicates. The inner ring represents the 34 chromosomes of <italic>L. mexicana</italic>. Multi-copy sgRNA targets are linked by coloured lines spanning the inner chromosome ring. The seven outer rings show results from (1-5) drug response screens (192 h vs. recovery 1 for MTF, AmB, PTM, 1c or Sb<sup>III</sup>), (6) the motility screen (144 h vs. upper transwell fraction), and (7) the viability screen (0 h vs. 360 h). The black line denotes the baseline (no enrichment or depletion). Data points (sgRNA sets) near the baseline are shown in lighter shades; significantly (log<sub>2</sub> p ≤−4.3219) enriched (above line) or depleted (below line) targets appear as darker-coloured dots. Genes exhibiting cross-resistance and/or collateral sensitivity are annotated with red numbers and their corresponding gene name is indicated.</p></caption><graphic xlink:href="EMS206974-f004"/></fig></floats-group></article>